Cabot Corp Reports Fourth Quarter Diluted Loss Per Share of ($4.81) and Adjusted EPS Of $0.68

Cabot Corp Reports Fourth Quarter Diluted Loss Per Share of ($4.81) and Adjusted EPS Of $0.68

Fiscal Year 2020 Diluted loss per share of ($4.21) andAdjusted EPS of $2.08

BOSTON–(BUSINESS WIRE)–Cabot Corporation (NYSE: CBT) today announced results for its fourth quarter and full fiscal year 2020.

Key Highlights

  • GAAP EPS was a loss of $4.81, compared to earnings of $0.55 in the prior fiscal year fourth quarter. Adjusted EPS of $0.68 compared to $1.05 in the prior fiscal year fourth quarter
  • Fiscal fourth quarter volumes in Reinforcement Materials rebounded strongly from the third quarter, increasing by 56%, and EBIT improved by $64 million
  • Continued strong operating cash flow of $99 million in the fourth quarter and $377 million for the full fiscal year
  • Liquidity remains strong at approximately $1.4 billion; Debt decreased by $69 million during the quarter; Debt to EBITDA ratio of 2.9 times as of September 30, 2020
  • Sold the Purification Solutions’ lignite mine in Marshall, TX to ADES and signed long-term product supply agreement

(In millions, except per share amounts)

Three Months Ended

 

Twelve Months Ended

 

9/30/20

 

9/30/19

 

9/30/20

 

9/30/19

 

 

Net sales

$

659

 

$

827

 

 

$

2,614

 

$

3,337

 

Net income (loss) attributable to Cabot Corporation

$

(272

)

$

33

 

 

$

(238

)

$

157

 

 

 

 

 

 

 

   

Net earnings (loss) per share attributable to Cabot Corporation

$

(4.81

)

$

0.55

 

 

$

(4.21

)

$

2.63

 

Less: Certain items after tax per share

$

(5.49

)

$

(0.50

)

 

$

(6.29

)

$

(1.28

)

Adjusted EPS

$

0.68

 

$

1.05

 

 

$

2.08

 

$

3.91

 

Commenting on the results, Cabot President and CEO Sean Keohane said, “I am very pleased to see the strong sequential demand momentum in the fourth quarter largely driven by an improving global economy and steady improvement in the tire and automotive sectors. I am also proud of our team’s ability to successfully manage the continued challenges from the COVID-19 global pandemic. As certain segments of the global economy gained momentum during the quarter, we responded quickly to serve increased customer demand. At the segment level, we experienced a significant sequential improvement in demand in Reinforcement Materials this quarter as customers increased their production levels. In Performance Chemicals, we saw a modest sequential improvement in volumes as key end markets begin to recover and in Purification Solutions, we executed the next step in our transformation plan by selling our lignite mine in Marshall, Texas and entering into a long-term supply agreement for activated carbon from ADES.”

Keohane continued, “Our working capital reduction efforts generated a strong source of cash in the fourth quarter which helped drive $99 million of operating cash flow in the quarter and $248 million in the second half of the fiscal year, well in excess of our previously announced expectation of $200 million. Our strong cash flow allowed us to reduce our debt, continue to pay our dividend and fund $38 million of capital expenditures in the quarter. Our balance sheet remains strong with approximately $1.4 billion of liquidity and a total debt to EBITDA ratio of 2.9x as of September 30, 2020. Our aggressive cost reduction efforts generated a savings of $68 million in fiscal 2020. As the global economy continues to recover, we believe we remain well positioned both strategically and financially.”

Financial Detail

For the fourth quarter of fiscal 2020, net loss attributable to Cabot Corporation was $272 million ($4.81 loss per diluted common share). The net loss includes a total after-tax per share charges from certain items of $5.49 predominantly from the loss on the sale and asset impairment related to the Purification Solutions agreements with ADES and tax certain items mainly associated with an increase in the valuation allowance associated with U.S. deferred tax assets. Adjusted EPS for the fourth quarter of fiscal 2020 was $0.68 per share.

Segment Results

Reinforcement Materials — Fourth quarter fiscal 2020 EBIT in Reinforcement Materials decreased by $12 million compared to the fourth quarter of fiscal 2019. Globally, volumes decreased 11% year-over-year as the COVID-19 pandemic impacted demand levels. The EBIT impact from lower volumes was partially offset by improved pricing from our calendar 2020 customer agreements and improved pricing in Asia.

Global and regional volume changes for Reinforcement Materials for the fourth quarter of fiscal 2020 as compared to the same quarter of the prior year are included in the table below:

 

Fourth Quarter

Year-over-Year Change

Changes in Global Reinforcement Materials Volumes

(11%)

Asia

(16%)

Europe, Middle East, Africa

(10%)

Americas

(5%)

Performance Chemicals Fourth quarter fiscal 2020 EBIT in Performance Chemicals decreased by $16 million compared to the fourth quarter of fiscal 2019 primarily due to a less favorable product mix in the specialty carbons and fumed metal oxides product lines, and by a more competitive pricing environment in our fumed metal oxides product line. Year-over-year, volumes decreased by 9% in the Formulated Solutions business driven by declines in our specialty compounds and inkjet product lines. These impacts were partially offset by 2% higher volumes in Performance Additives driven by increased volumes related to our recent energy materials acquisition.

Purification Solutions Fourth quarter fiscal 2020 EBIT in Purification Solutions decreased by $3 million compared to the fourth quarter of fiscal 2019 primarily due to the impact from reducing inventory levels to drive strong cash flow.

Cash PerformanceThe Company ended the fourth quarter of fiscal 2020 with a cash balance of $151 million. During the fourth quarter of fiscal 2020, cash flows from operating activities were $99 million, which included a $7 million decrease in net working capital. Capital expenditures for the fourth quarter of fiscal 2020 were $38 million. Additional uses of cash during the fourth quarter included $20 million for the payment of dividends.

Taxes During the fourth quarter of fiscal 2020, the Company recorded a tax provision of $182 million for an effective tax rate of (217%).The provision included a $166 million net charge from tax-related certain items. The operating tax rate for fiscal year 2020 was 28% and we anticipate our operating tax rate for fiscal 2021 to be in the range of 28% to 30%.

Outlook

Commenting on the outlook for the Company, Keohane said, “As we enter fiscal 2021, we are encouraged by the pace of recovery we are seeing in the automotive and tire markets. With this momentum, we expect both year-over-year and sequential EBIT improvement as we look ahead to the first quarter of fiscal 2021. Reinforcement Materials is expected to benefit from improved margins, particularly in Asia, and we anticipate that Performance Chemicals will benefit in both volumes and product mix from a strengthening automotive end market. Based on the current market environment, we expect adjusted earnings per share in the first fiscal quarter to be between $0.80 and $0.90. This expectation assumes that the resurgence in COVID-19 infections will not cause a significant disruption to the ongoing business recovery. Due to continued economic uncertainty related to the impacts of the COVID-19 pandemic, we are not providing fiscal 2021 full-year earnings guidance at this time.”

Keohane continued, “Our team remains focused on executing our Advancing the Core strategyand emerging from this crisis an even stronger company. Our long-term growth strategy and capital allocation framework guides our actions and is underpinned by strong cash flow discipline and the strength of our investment grade balance sheet. We plan to continue to invest in attractive growth projects across our core segments while exploring strategic alternatives for our Purification Solutions business. We remain committed to returning cash to our shareholders as part of our balanced capital allocation framework and maintaining our investment grade credit rating. I am confident in the fundamental earnings power of our businesses and our long-term growth prospects.”

Earnings Call

The Company will host a conference call with industry analysts at 8:00 a.m. Eastern time on Tuesday, November 24, 2020. The call can be accessed through Cabot’s investor relations website at http://investor.cabot-corp.com

About Cabot Corporation

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company is a leading provider of carbon black, specialty carbons, activated carbon, elastomer composites, inkjet colorants, masterbatches and conductive compounds, fumed silica and aerogel. For more information on Cabot, please visit the company’s website at cabotcorp.com. The Company encourages investors and potential investors to consult the Cabot website regularly.

Forward-Looking Statements — This earnings release contains forward-looking statements. All statements that address expectations or projections about the future, including our expectations for EBIT, margins, volume and product mix improvements in certain of our businesses in the first quarter of fiscal 2021, our expectations for Adjusted EPS for the first quarter of fiscal 2021, the factors we expect to positively impact our results, capital allocation, our earnings potential and growth prospects, and our expected operating tax rate for fiscal 2021, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, potentially inaccurate assumptions, and other factors, some of which are beyond our control and difficult to predict. If known or unknown risks materialize, or should underlying assumptions prove inaccurate, our actual results could differ materially from past results and from those expressed or implied by forward-looking statements. Importantly, as we cannot predict the duration or scope of the COVID-19 pandemic, the negative impact to our results cannot be estimated. Factors that will influence the impact on our business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. Other important factors that could cause our results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to, competition from other specialty chemical companies; volatility in the price of energy and raw materials; a significant adverse change in a customer relationship; safety, health and environmental requirements; unanticipated delays in site development projects; negative or uncertain worldwide or regional economic conditions and market opportunities, including from trade relations or global health matters; and fluctuations in foreign currency exchange and interest rates. These factors are discussed more fully in the reports we file with the Securities and Exchange Commission (“SEC”), particularly under the heading “Risk Factors” in our annual report on Form 10-K for our fiscal year ended September 30, 2019 and in our quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2020, or subsequent SEC filings, filed with the SEC at www.sec.gov. We assume no obligation to provide revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

Use of Non-GAAP Financial Measures

To supplement Cabot’s consolidated financial statements presented on a generally accepted accounting principle (“GAAP”) basis, the preceding discussion of our results and the accompanying financial tables report Adjusted EPS, Total Segment EBIT, Total Segment EBITDA, Adjusted EBITDA, Adjusted EPS excluding the Specialty Fluids segment, our operating tax rate, Free Cash Flow and Discretionary Free Cash Flow, all of which are non-GAAP financial measures. These non-GAAP financial measures are not computed in accordance with, or as an alternative to, GAAP. Reconciliations of Adjusted EPS and adjusted EPS excluding the Specialty Fluids segment to net income (loss) per share attributable to Cabot Corporation, the most directly comparable GAAP financial measure of both such non-GAAP measures, Total Segment EBIT, Total Segment EBITDA, and Adjusted EBITDA to income (loss) before income taxes and equity in earnings of affiliated companies, the most directly comparable GAAP financial measure of each such non-GAAP measure, operating tax rate to effective tax rate, the most directly comparable GAAP financial measure and Free Cash Flow and Discretionary Free Cash Flow to Cash flow from operating activities, the most directly comparable GAAP financial measure of both such non-GAAP measures, are provided in the tables titled “Cabot Corporation Certain Items and Reconciliation of Adjusted EPS and Operating Tax Rate” and “Cabot Corporation Reconciliation of Non-GAAP Financial Measures.”

Management believes these non-GAAP measures provide investors with greater transparency to the information used by Cabot management in its financial and operational decision-making, allow investors to see Cabot’s results through the eyes of management, and better enable Cabot’s investors to understand Cabot’s operating performance and financial condition.

Adjusted EPS. In calculating Adjusted EPS, we exclude from our net income (loss) attributable to Cabot Corporation items of expense and income that management does not consider representative of the Company’s business operations. Accordingly, reporting earnings on an adjusted basis supplements the GAAP measure of performance and provides additional information related to the underlying performance of the business. For example, certain of the items we exclude are items that we are required by GAAP to recognize in one period that relate to activities extending over several periods or relate to single events that management considers to be unusual and infrequent, although not necessarily non-recurring. We refer to these items as “certain items.” Management believes excluding these items facilitates operating performance comparisons from period to period by eliminating differences caused by the existence and timing of certain expense and income items that would not otherwise be apparent on a GAAP basis and evaluates the Company’s operating performance without the impact of these costs or benefits. Management also uses Adjusted EPS as a key measure in evaluating management performance for incentive compensation purposes.

The items of income and expense that we exclude from our calculations of Adjusted EPS, as applicable, but that are included in our GAAP net income (loss) per share, as applicable, are described below.

  • Asset impairment charges, which primarily include charges associated with an impairment of goodwill or other long-lived assets.
  • Inventory reserve adjustment, which result from an evaluation performed as part of an impairment analysis.
  • Global restructuring activities, which include costs or benefits associated with cost reduction initiatives or plant closures and primarily relate to (i) employee termination costs, (ii) asset impairment charges associated with restructuring actions, (iii) costs to close facilities, including environmental costs and contract termination penalties, and (iv) gains realized on the sale of land or equipment associated with restructured plants or locations.
  • Legal and environmental reserves and matters, which consist of costs or benefits for matters typically related to former businesses or that were otherwise incurred outside of the ordinary course of business.
  • Gains (losses) on sale of investments, which primarily relate to the sale of investments accounted for under the cost-method.
  • Gains (losses) on sale of businesses
  • Executive transition costs, which include incremental charges, including stock compensation charges, associated with the retirement or termination of employment of senior executives of the Company.
  • Acquisition and integration-related charges, which include transaction costs, redundant costs incurred during the period of integration, and costs associated with transitioning certain management and business processes to Cabot’s processes.
  • Non-recurring gains (losses) on foreign currency, which primarily relate to the impact of continued currency devaluations on our net monetary assets denominated in that currency.
  • Employee benefit plan settlements and other charges, which consist of either charges or benefits associated with the termination of a pension plan or the transfer of a pension plan to a multi-employer plan or prior service cost charges associated with a change in assumption on a frozen pension plan
  • Indirect tax settlement credits, which includes favorable settlements resulting in the recoveries of indirect taxes.
  • Certain valuation allowances on deferred tax assets earned in the current fiscal year.

Cabot does not provide a target GAAP EPS range or reconciliation of the Adjusted EPS range with a GAAP EPS range because, without unreasonable effort, we are unable to predict with reasonable certainty the matters we would allocate to “certain items,” including unusual gains and losses, costs associated with future restructurings, acquisition-related expenses and litigation outcomes. These items are uncertain, depend on various factors, and could have a material impact on GAAP EPS in future periods.

Total Segment EBIT. Total segment EBIT reflects the sum of EBIT from our three reportable segments. In calculating Total segment EBIT we exclude from our income (loss) before income taxes and equity in earnings of affiliated companies, certain items and items that, because they are not controlled by the business segments and primarily benefit corporate objectives, are not allocated to our business segments, such as interest expense and other corporate costs, which include unallocated corporate overhead expenses such as certain corporate salaries and headquarter expenses, plus costs related to corporate projects and initiatives.

Total Segment EBITDA. Total Segment EBITDA is equal to Total Segment EBIT (as defined above), but further adjusted for depreciation and amortization.

Adjusted EBITDA. Adjusted EBITDA reflects Total Segment EBITDA and is further adjusted for unallocated corporate costs, which include unallocated corporate overhead expenses such as certain corporate salaries and headquarter expenses, plus costs related to corporate projects and initiatives.

Free Cash Flow. To calculate “free cash flow” we deduct capital expenditures from cash flow from operating activities.

Discretionary Free Cash Flow. To calculate “Discretionary Free Cash Flow” we deduct sustaining and compliance capital expenditures and changes in Net Working Capital from cash flow from operating activities.

Operating Tax Rate. Our “operating tax rate” represents the tax rate on our recurring operating results. This rate excludes discrete tax items, which are unusual or infrequent items that are excluded from the estimated annual effective tax rate and other tax items, including the impact of the timing of losses in certain jurisdictions, cumulative tax rate adjustments and the impact of the items of expense and income we identify as certain items on both our operating income and the tax provision. In addition, in fiscal 2020 we have excluded certain valuation allowances on deferred tax assets earned in the current fiscal year. Management believes that the operating tax rate is useful supplemental information because it helps our investors compare our tax rate year to year on a consistent basis and to understand what our tax rate on current operations would be without the impact of these items.

Cabot does not provide a forward-looking reconciliation of the operating tax rate range with an effective tax rate range because, without unreasonable effort, we are unable to predict with reasonable certainty the matters we would allocate to “certain items,” including unusual gains and losses, costs associated with future restructurings, acquisition-related expenses and litigation outcomes. These items are uncertain, depend on various factors, and could have a material impact on the effective tax rate in future periods.

Explanation of Terms Used

Product Mix. The term “product mix” refers to the mix of types and grade of products sold or the mix of geographic regions where products are sold, and the positive or negative impact this has on the revenue or profitability of the business or segment.

Net Working Capital. The term “net working capital” includes accounts receivable, inventory and accounts payable and accrued liabilities.

Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS
 
 
Periods ended September 30 Three Months Twelve Months
Dollars in millions, except per share amounts (unaudited)

2020

2019

2020

2019

 
Net sales and other operating revenues

$

659

 

$

827

 

$

2,614

 

$

3,337

 

 
Cost of sales

 

522

 

 

656

 

 

2,114

 

 

2,652

 

 
Gross profit

 

137

 

 

171

 

 

500

 

 

685

 

 
Selling and administrative expenses

 

62

 

 

82

 

 

292

 

 

290

 

 
Research and technical expenses

 

16

 

 

13

 

 

57

 

 

60

 

 
Specialty Fluids loss on sale and asset impairment charge

 

 

 

1

 

 

1

 

 

29

 

 
Marshall Mine loss on sale and asset impairment charge

 

129

 

 

 

 

129

 

 

 

 
Income (loss) from operations

 

(70

)

 

75

 

 

21

 

 

306

 

 
Other income (expense)
 
Interest and dividend income

 

1

 

 

3

 

 

8

 

 

9

 

 
Interest expense

 

(12

)

 

(16

)

 

(53

)

 

(59

)

 
Other income (expense)

 

(3

)

 

5

 

 

(9

)

 

(1

)

 
Total other income (expense)

 

(14

)

 

(8

)

 

(54

)

 

(51

)

 
Income (loss) before income taxes and equity in
earnings of affiliated companies

 

(84

)

 

67

 

 

(33

)

 

255

 

 
(Provision) benefit for income taxes

 

(182

)

 

(27

)

 

(191

)

 

(70

)

 
Equity in earnings of affiliated companies, net of tax

 

1

 

 

 

 

3

 

 

1

 

 
Net income (loss)

 

(265

)

 

40

 

 

(221

)

 

186

 

 
Net income (loss) attributable to noncontrolling interests

 

7

 

 

7

 

 

17

 

 

29

 

 
Net income (loss) attributable to Cabot Corporation

$

(272

)

$

33

 

$

(238

)

$

157

 

 
Diluted earnings (loss) per share of common stock
attributable to Cabot Corporation

$

(4.81

)

$

0.55

 

$

(4.21

)

$

2.63

 

 
Diluted weighted average common shares outstanding

 

56.5

 

 

57.6

 

 

56.6

 

 

58.8

 

 

Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION SUMMARY RESULTS BY SEGMENT
 
 
Periods ended September 30 Three Months Twelve Months
Dollars in millions, except per share amounts (unaudited)

2020

2019

2020

2019

 
Sales
 
Reinforcement Materials

$

325

 

$

452

 

$

1,256

 

$

1,815

 

 
Performance Chemicals

 

226

 

 

259

 

 

933

 

 

995

 

 
Performance Additives

 

156

 

 

176

 

 

645

 

 

694

 

 
Formulated Solutions

 

70

 

 

83

 

 

288

 

 

301

 

 
Purification Solutions

 

67

 

 

68

 

 

253

 

 

278

 

 
Specialty Fluids (A)

 

 

 

 

 

 

 

56

 

 
Segment sales

 

618

 

 

779

 

 

2,442

 

 

3,144

 

 
Unallocated and other (B)

 

41

 

 

48

 

 

172

 

 

193

 

 
Net sales and other operating revenues

$

659

 

$

827

 

$

2,614

 

$

3,337

 

 
Segment Earnings Before Interest and Taxes (C)
 
Reinforcement Materials

$

59

 

$

71

 

$

162

 

$

266

 

 
Performance Chemicals

 

25

 

 

41

 

 

118

 

 

152

 

 
Purification Solutions

 

 

 

3

 

 

3

 

 

2

 

 
Specialty Fluids (A)

 

 

 

 

 

 

 

24

 

 
Total Segment Earnings Before Interest and Taxes

 

84

 

 

115

 

 

283

 

 

444

 

 
Unallocated and Other
 
Interest expense

 

(12

)

 

(16

)

 

(53

)

 

(59

)

 
Certain items (D)

 

(144

)

 

(26

)

 

(218

)

 

(87

)

 
Unallocated corporate costs

 

(9

)

 

(11

)

 

(41

)

 

(50

)

 
General unallocated income (expense) (E)

 

(2

)

 

5

 

 

(1

)

 

8

 

 
Less: Equity in earnings of affiliated companies

 

1

 

 

 

 

3

 

 

1

 

 
Income (loss) before income taxes and equity in
earnings of affiliated companies

 

(84

)

 

67

 

 

(33

)

 

255

 

 
(Provision) benefit for income taxes (including tax certain items)

 

(182

)

 

(27

)

 

(191

)

 

(70

)

 
Equity in earnings of affiliated companies

 

1

 

 

 

 

3

 

 

1

 

 
Net income (loss)

 

(265

)

 

40

 

 

(221

)

 

186

 

 
Net income attributable to noncontrolling interests

 

7

 

 

7

 

 

17

 

 

29

 

 
Net income (loss) attributable to Cabot Corporation

$

(272

)

$

33

 

$

(238

)

$

157

 

 
Diluted earnings (loss) per share of common stock
attributable to Cabot Corporation

$

(4.81

)

$

0.55

 

$

(4.21

)

$

2.63

 

 
Adjusted earnings (loss) per share (F)

$

0.68

 

$

1.05

 

$

2.08

 

$

3.91

 

 
Diluted weighted average common shares outstanding

 

56.5

 

 

57.6

 

 

56.6

 

 

58.8

 

(A)

Cabot divested its Specialty Fluids business, which does not meet the criteria to be reported as a discontinued operation, during the third quarter of fiscal 2019. Therefore, prior periods’ financial statements and disclosures have not been recast. For more detail on the sale of the Specialty Fluids business, please refer to the Company’s fiscal 2019 10-K filing.

(B)

Unallocated and other reflects royalties, other operating revenues, external shipping and handling fees, the impact of the corporate adjustment for unearned revenue, the removal of 100% of the sales of an equity method affiliate, and discounting charges for certain Notes receivable.

(C)

Segment EBIT is a measure used by Cabot’s Chief Operating Decision-Maker to measure consolidated operating results, assess segment performance and allocate resources. Segment EBIT includes equity in earnings of affiliated companies, royalty income, and allocated corporate costs.

(D)

Details of Certain items are presented in the Certain Items and Reconciliation of Adjusted EPS and Operating Tax Rate table.

(E)

General unallocated income (expense) consists of gains (losses) arising from foreign currency transactions, net of other foreign currency risk management activities, Interest and dividend income, the profit or loss related to the corporate adjustment for unearned revenue, the impact of including the full operating results of a contractual joint venture in Purification Solutions Segment EBIT and unrealized holding gains (losses) for equity securities.

(F)

Adjusted EPS is a non-GAAP measure, and a reconciliation of Adjusted EPS to GAAP EPS is presented in the Certain Items and Reconciliation of Adjusted EPS and Operating Tax Rate table.
Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
 
 
September 30, September 30,
Dollars in millions (unaudited)

2020

2019

 
Current assets:
 
Cash and cash equivalents

$

151

$

169

 
Accounts and notes receivable, net of reserve for doubtful accounts of $2 and $3

 

418

 

530

 
Inventories:
 
Raw materials

 

82

 

107

 
Finished goods

 

225

 

305

 
Other

 

52

 

54

 
Total inventories

 

359

 

466

 
Prepaid expenses and other current assets

 

50

 

45

 
Total current assets

 

978

 

1,210

 
Property, plant and equipment, net

 

1,314

 

1,348

 
Goodwill

 

134

 

90

 
Equity affiliates

 

39

 

39

 
Intangible assets, net

 

103

 

96

 
Deferred income taxes

 

53

 

163

 
Other assets (A)

 

160

 

58

 
Total assets

$

2,781

$

3,004

(A) Effective October 1, 2019, the Company adopted the new accounting standard for leases and applied the modified retrospective optional transition method. As such, operating lease right of use assets of $98 million are included in Other assets as of September 30, 2020, and the prior period has not been restated.
Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
 
 
September 30, September 30,
Dollars in millions, except share and per share amounts (unaudited)

2020

2019

 
Current liabilities:
 
Short-term borrowings

$

14

 

$

33

 

 
Accounts payable and accrued liabilities (A)

 

488

 

 

537

 

 
Income taxes payable

 

20

 

 

22

 

 
Current portion of long-term debt

 

7

 

 

7

 

 
Total current liabilities

 

529

 

 

599

 

 
Long-term debt

 

1,094

 

 

1,024

 

 
Deferred income taxes

 

58

 

 

41

 

 
Other liabilities (A)

 

286

 

 

206

 

 
Stockholders’ equity:
 
Preferred stock:
Authorized: 2,000,000 shares of $1 par value
Issued and Outstanding: None and none

 

 

 

 

 
Common stock:
Authorized: 200,000,000 shares of $1 par value, Issued: 56,616,030 and 57,250,454 shares
Outstanding: 56,466,638 and 57,080,589 shares

 

57

 

 

57

 

 
Less cost of 149,392 and 169,865 shares of common treasury stock

 

(4

)

 

(5

)

 
Additional paid-in capital

 

 

 

 

 
Retained earnings

 

989

 

 

1,337

 

 
Accumulated other comprehensive income (loss)

 

(351

)

 

(391

)

 
Total Cabot Corporation stockholders’ equity

 

691

 

 

998

 

 
Noncontrolling interests

 

123

 

 

136

 

 
Total stockholders’ equity

 

814

 

 

1,134

 

 
Total liabilities and stockholders’ equity

$

2,781

 

$

3,004

 

(A) Effective October 1, 2019, the Company adopted the new accounting standard for leases and applied the modified retrospective optional transition method. As such, operating lease liabilities of $15 million and $89 million are included in Accounts payable and accrued liabilities and Other liabilities, respectively, as of September 30, 2020, and the prior period has not been restated.
Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION QUARTERLY RESULTS BY SEGMENT
 
 
Fiscal 2019 Fiscal 2020
Dollars in millions,
except per share amounts (unaudited) Dec. Q Mar. Q June Q Sept. Q FY Dec. Q Mar. Q June Q Sept. Q FY
 
Sales
Reinforcement Materials

$

457

 

$

445

 

$

461

 

$

452

 

$

1,815

 

$

379

 

$

355

 

$

197

 

$

325

 

$

1,256

 

Performance Chemicals

 

231

 

 

254

 

 

251

 

 

259

 

 

995

 

 

242

 

 

245

 

 

220

 

 

226

 

 

933

 

Performance Additives

 

167

 

 

179

 

 

172

 

 

176

 

 

694

 

 

170

 

 

168

 

 

151

 

 

156

 

 

645

 

Formulated Solutions

 

64

 

 

75

 

 

79

 

 

83

 

 

301

 

 

72

 

 

77

 

 

69

 

 

70

 

 

288

 

Purification Solutions

 

65

 

 

72

 

 

73

 

 

68

 

 

278

 

 

59

 

 

64

 

 

63

 

 

67

 

 

253

 

Specialty Fluids (A)

 

19

 

 

24

 

 

13

 

 

 

 

56

 

 

 

 

 

 

 

 

 

 

 

Segment sales

 

772

 

 

795

 

 

798

 

 

779

 

 

3,144

 

 

680

 

 

664

 

 

480

 

 

618

 

 

2,442

 

Unallocated and other (B)

 

49

 

 

49

 

 

47

 

 

48

 

 

193

 

 

47

 

 

46

 

 

38

 

 

41

 

 

172

 

 
Net sales and other operating revenues

$

821

 

$

844

 

$

845

 

$

827

 

$

3,337

 

$

727

 

$

710

 

$

518

 

$

659

 

$

2,614

 

 
Segment Earnings Before Interest and Taxes (C)
Reinforcement Materials

$

62

 

$

61

 

$

72

 

$

71

 

$

266

 

$

47

 

$

61

 

$

(5

)

$

59

 

$

162

 

Performance Chemicals

 

36

 

 

38

 

 

37

 

 

41

 

 

152

 

 

41

 

 

31

 

 

21

 

 

25

 

 

118

 

Purification Solutions

 

(3

)

 

1

 

 

1

 

 

3

 

 

2

 

 

(2

)

 

3

 

 

2

 

 

 

 

3

 

Specialty Fluids (A)

 

10

 

 

12

 

 

2

 

 

 

 

24

 

 

 

 

 

 

 

 

 

 

 

Total Segment Earnings Before Interest and Taxes

 

105

 

 

112

 

 

112

 

 

115

 

 

444

 

 

86

 

 

95

 

 

18

 

 

84

 

 

283

 

 
Unallocated and Other
Interest expense

 

(15

)

 

(14

)

 

(14

)

 

(16

)

 

(59

)

 

(14

)

 

(14

)

 

(13

)

 

(12

)

 

(53

)

Certain items (D)

 

(10

)

 

(37

)

 

(14

)

 

(26

)

 

(87

)

 

(11

)

 

(56

)

 

(7

)

 

(144

)

 

(218

)

Unallocated corporate costs

 

(12

)

 

(13

)

 

(14

)

 

(11

)

 

(50

)

 

(10

)

 

(12

)

 

(10

)

 

(9

)

 

(41

)

General unallocated income (expense) (E)

 

2

 

 

1

 

 

 

 

5

 

 

8

 

 

(1

)

 

 

 

2

 

 

(2

)

 

(1

)

Less: Equity in earnings of affiliated companies

 

 

 

 

 

1

 

 

 

 

1

 

 

 

 

1

 

 

1

 

 

1

 

 

3

 

 
Income (loss) before income taxes and
equity in earnings of affiliated companies

 

70

 

 

49

 

 

69

 

 

67

 

 

255

 

 

50

 

 

12

 

 

(11

)

 

(84

)

 

(33

)

 

 

 

 

 

 

 

 

(Provision) benefit for income taxes (including tax certain items)

 

7

 

 

(20

)

 

(30

)

 

(27

)

 

(70

)

 

(4

)

 

(10

)

 

5

 

 

(182

)

 

(191

)

Equity in earnings of affiliated companies

 

 

 

 

 

1

 

 

 

 

1

 

 

 

 

1

 

 

1

 

 

1

 

 

3

 

 
Net income (loss)

 

77

 

 

29

 

 

40

 

 

40

 

 

186

 

 

46

 

 

3

 

 

(5

)

 

(265

)

 

(221

)

 
Net income (loss) attributable to noncontrolling interests

 

8

 

 

6

 

 

8

 

 

7

 

 

29

 

 

5

 

 

4

 

 

1

 

 

7

 

 

17

 

 
Net income (loss) attributable to Cabot Corporation

$

69

 

$

23

 

$

32

 

$

33

 

$

157

 

$

41

 

$

(1

)

$

(6

)

$

(272

)

$

(238

)

 
Diluted earnings (loss) per share of common stock
attributable to Cabot Corporation

$

1.14

 

$

0.39

 

$

0.55

 

$

0.55

 

$

2.63

 

$

0.70

 

$

(0.01

)

$

(0.12

)

$

(4.81

)

$

(4.21

)

 
Adjusted earnings (loss) per share (F)

$

0.87

 

$

0.99

 

$

1.00

 

$

1.05

 

$

3.91

 

$

0.69

 

$

0.77

 

$

(0.07

)

$

0.68

 

$

2.08

 

 
Diluted weighted average common shares outstanding

 

60.1

 

 

59.3

 

 

58.4

 

 

57.6

 

 

58.8

 

 

57.0

 

 

56.6

 

 

56.5

 

 

56.5

 

 

56.6

 

(A)

Cabot divested its Specialty Fluids business, which does not meet the criteria to be reported as a discontinued operation, during the third quarter of fiscal 2019. Therefore, prior periods’ financial statements and disclosures have not been recast. For more detail on the sale of the Specialty Fluids business, please refer to the Company’s fiscal 2019 10-K filing.

(B)

Unallocated and other reflects royalties, other operating revenues, external shipping and handling fees, the impact of the corporate adjustment for unearned revenue, the removal of 100% of the sales of an equity method affiliate and discounting charges for certain Notes receivable.

(C)

Segment EBIT is a measure used by Cabot’s Chief Operating Decision-Maker to measure consolidated operating results, assess segment performance and allocate resources. Segment EBIT includes equity in earnings of affiliated companies, royalty income, and allocated corporate costs.

(D)

Details of certain items are presented in the Certain Items and Reconciliation of Adjusted EPS and Operating Tax Rate table.

(E)

General unallocated income (expense) consists of gains (losses) arising from foreign currency transactions, net of other foreign currency risk management activities, Interest and dividend income, the profit or loss related to the corporate adjustment for unearned revenue, the impact of including the full operating results of a contractual joint venture in Purification Solutions Segment EBIT and unrealized holding gains (losses) for equity securities.

(F)

Adjusted EPS is a non-GAAP measure, and a reconciliation of Adjusted EPS to GAAP EPS is presented in the Certain Items and Reconciliation of Adjusted EPS and Operating Tax Rate table.
Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 
 
Periods ended September 30

Three Months

Twelve Months

Dollars in millions (unaudited)

2020

2019

2020

2019

 
Cash Flows from Operating Activities:
 
Net income (loss)

$

(265

)

$

40

 

$

(221

)

$

186

 

 
Adjustments to reconcile net income to cash provided by operating activities:
 
Depreciation and amortization

 

41

 

 

38

 

 

158

 

 

148

 

 
Other non-cash charges, net

 

290

 

 

(6

)

 

277

 

 

27

 

 

Cash dividends received from equity affiliates

 

 

 

 

 

1

 

 

2

 

 
Changes in assets and liabilities:
 
Changes in certain working capital items (A)

 

7

 

 

98

 

 

185

 

 

25

 

 
Changes in other assets and liabilities, net

 

26

 

 

27

 

 

(23

)

 

(25

)

 
Cash provided by (used in) operating activities

 

99

 

 

197

 

 

377

 

 

363

 

 
Cash Flows from Investing Activities:
 
Additions to property, plant and equipment

 

(38

)

 

(69

)

 

(200

)

 

(224

)

 
Proceeds from sale of business

 

 

 

5

 

 

 

 

135

 

 
Cash paid for acquisition of business, net of cash acquired of $0, $0, $1 and $0

 

 

 

 

 

(92

)

 

(3

)

 
Other investing activities, net

 

2

 

 

3

 

 

4

 

 

(2

)

 
Cash provided by (used in) investing activities

 

(36

)

 

(61

)

 

(288

)

 

(94

)

 
Cash Flows from Financing Activities:
 
Change in debt, net

 

(75

)

 

(43

)

 

15

 

 

61

 

 
Cash dividends paid to common stockholders

 

(20

)

 

(20

)

 

(80

)

 

(80

)

 
Other financing activities, net

 

 

 

(27

)

 

(67

)

 

(217

)

 
Cash provided by (used in) financing activities

 

(95

)

 

(90

)

 

(132

)

 

(236

)

 
Effect of exchange rates on cash

 

21

 

 

(24

)

 

25

 

 

(39

)

 
Increase (decrease) in cash and cash equivalents

 

(11

)

 

22

 

 

(18

)

 

(6

)

 
Cash and cash equivalents at beginning of period

 

162

 

 

147

 

 

169

 

 

175

 

 
Cash and cash equivalents at end of period

$

151

 

$

169

 

$

151

 

$

169

 

(A) Includes Accounts and notes receivable, Inventories, and Accounts payable and accrued liabilities.
Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION CERTAIN ITEMS AND RECONCILIATION OF ADJUSTED EPS AND OPERATING TAX RATE
 
 
TABLE 1: DETAIL OF CERTAIN ITEMS
Periods ended September 30

Three Months

Twelve Months

Dollars in millions, except per share amounts (unaudited)

2020

2019

2020

2019

 
Certain items before and after income taxes
 
Marshall Mine loss on sale and asset impairment charge

$

(129

)

$ ―

$

(129

)

$ ―
Legal and environmental matters and reserves

 

(3

)

 

(20

)

 

(54

)

 

(21

)

Global restructuring activities

 

(3

)

 

(1

)

 

(19

)

 

(16

)

Employee benefit plan settlement and other charges

 

(5

)

 

 

 

(10

)

 

1

 

Acquisition and integration-related charges

 

(2

)

 

(1

)

 

(5

)

 

(6

)

Inventory reserve adjustment

 

(2

)

 

 

 

(2

)

 

 

Specialty Fluids loss on sale and asset impairment charges

 

 

 

(1

)

 

(1

)

 

(29

)

Equity affiliate investment impairment charge

 

 

 

 

 

 

 

(11

)

Executive transition costs

 

 

 

(1

)

 

 

 

(1

)

Indirect tax settlement credits

 

 

 

 

 

3

 

 

 

Other certain items

 

 

 

(2

)

 

(1

)

 

(4

)

Total certain items, pre-tax

 

(144

)

 

(26

)

 

(218

)

 

(87

)

 
Tax impact of certain items (A)

 

(12

)

 

3

 

 

 

 

7

 

Tax certain item (B)

 

(17

)

 

 

 

(17

)

 

 

Certain items after tax (excluding discrete tax items)

 

(173

)

 

(23

)

 

(235

)

 

(80

)

Certain items after tax per share impact (excluding discrete tax items)

$

(3.06

)

$

(0.41

)

$

(4.13

)

$

(1.36

)

 
Discrete tax items

 

(137

)

 

(5

)

 

(122

)

 

5

 

Discrete tax items per share impact

 

(2.43

)

 

(0.09

)

 

(2.16

)

 

0.08

 

 
Total certain items after tax

$

(310

)

$

(28

)

$

(357

)

$

(75

)

Total certain items after tax per share impact

$

(5.49

)

$

(0.50

)

$

(6.29

)

$

(1.28

)

 
TABLE 2: CERTAIN ITEMS STATEMENT OF OPERATIONS LINE ITEM
Periods ended September 30 Three Months Twelve Months
Dollars in millions, Pre-Tax (unaudited)

2020

2019

2020

2019

 
Statement of Operations Line Item (C)
 
Cost of sales

$

(3

)

$

(5

)

$

(9

)

$

(18

)

Selling and administrative expenses

 

(6

)

 

(20

)

 

(68

)

 

(29

)

Research and technical expenses

 

 

 

 

 

 

 

(1

)

Other income (expense)

 

(6

)

 

 

 

(11

)

 

(10

)

Specialty Fluids loss on sale and asset impairment charges

 

 

 

(1

)

 

(1

)

 

(29

)

Marshall Mine loss on sale and asset impairment charges

 

(129

)

 

 

 

(129

)

 

 

Total certain items, pre-tax

$

(144

)

$

(26

)

$

(218

)

$

(87

)

 
TABLE 3: RECONCILIATION OF TAX CERTAIN ITEMS
Periods ended September 30 Three Months Twelve Months
Dollars in millions (unaudited)

2020

2019

2020

2019

 
Reconciliation of Provision for income taxes, excluding certain
items, to Provision for income taxes
 
 
(Provision) benefit for income taxes

$

(182

)

$

(27

)

$

(191

)

$

(70

)

 
Less: Tax impact of certain items

 

(12

)

 

3

 

 

 

 

7

 

 
Less: Tax certain item

 

(17

)

 

 

 

(17

)

 

 

 
Less: Discrete tax items

 

(137

)

 

(5

)

 

(122

)

 

5

 

 
(Provision) benefit for income taxes, excluding certain items

$

(16

)

$

(25

)

$

(52

)

$

(82

)

 
TABLE 4: RECONCILIATION OF OPERATING TAX RATE
Periods ended September 30 Three Months Twelve Months
Dollars in millions (unaudited)

2020

2019

2020

2019

 
Reconciliation of the effective tax rate to the operating tax rate (D)
 
 
(Provision) benefit for income taxes

$

(182

)

$

(27

)

$

(191

)

$

(70

)

 
Effective tax rate

 

(217

)%

 

41

%

 

(587

)%

 

28

%

 
Impact of discrete tax items: (E)
Unusual or infrequent items

 

161

%

 

%

 

397

%

 

2

%

Items related to uncertain tax positions

 

1

%

 

2

%

 

(22

)%

 

2

%

Other discrete tax items

 

2

%

 

(14

)%

 

1

%

 

(2

)%

Impact of certain items (F)

 

81

%

 

(5

)%

 

239

%

 

(6

)%

Operating tax rate

 

28

%

 

24

%

 

28

%

 

24

%

 
TABLE 5: RECONCILIATION OF ADJUSTED EPS BY QUARTER FOR FISCAL 2020 and FISCAL 2019
Fiscal 2020 (G)
Periods ended (unaudited) Dec. Q Mar. Q June Q Sept. Q FY 2020
Reconciliation of Adjusted EPS to GAAP EPS
Net income (loss) per share attributable to Cabot Corporation

$

0.70

 

$

(0.01

)

$

(0.12

)

$

(4.81

)

$

(4.21

)

Less: Certain items after tax per share

 

0.01

 

 

(0.78

)

 

(0.05

)

 

(5.49

)

 

(6.29

)

Adjusted earnings (loss) per share

$

0.69

 

$

0.77

 

$

(0.07

)

$

0.68

 

$

2.08

 

 
Fiscal 2019 (G)
Periods ended (unaudited) Dec. Q Mar. Q June Q Sept. Q FY 2019
Reconciliation of Adjusted EPS to GAAP EPS
Net income (loss) per share attributable to Cabot Corporation

$

1.14

 

$

0.39

 

$

0.55

 

$

0.55

 

$

2.63

 

Less: Certain items after tax per share

 

0.27

 

 

(0.60

)

 

(0.45

)

 

(0.50

)

 

(1.28

)

Adjusted earnings (loss) per share

$

0.87

 

$

0.99

 

$

1.00

 

$

1.05

 

$

3.91

 

(A)

The tax impact of certain items is determined by (1) starting with the current and deferred income tax expense or benefit, included in Net income attributable to Cabot Corporation, and (2) subtracting the tax expense or benefit on “adjusted earnings”. Adjusted earnings is defined as the pre-tax income attributable to Cabot Corporation excluding certain items. The tax expense or benefit on adjusted earnings is calculated by applying the operating tax rate, which includes both current and deferred taxes, as defined under the section Use of Non-GAAP Financial Measures of the earnings release.

(B)

The tax certain item represents a valuation allowance charge recorded against U.S. deferred tax assets earned in fiscal 2020.

(C)

This table indicates the line items where certain items are recorded in the Consolidated Statements of Operations.

(D)

Our operating tax rate for fiscal 2021 is expected to be in the range of 28% to 30%.

(E)

For fiscal 2020 and 2019, the impact of discrete tax items included a net discrete tax provision of $122 million and a net discrete tax benefit of $5 million, respectively. The nature of the discrete tax items for fiscal 2020 and 2019 were as follows: (i) Unusual or infrequent items during fiscal 2020 consisted of changes in valuation allowances on beginning of year tax balances, the net tax impacts of newly issued U.S. tax regulations, and the net tax impact of Switzerland tax reform legislation. Unusual or infrequent items during fiscal 2019 consisted of changes in valuation allowances on beginning of year tax balances, excludible foreign exchange gains and losses in certain jurisdictions, impacts related to stock compensation deductions, and the tax impacts of a pension settlement; (ii) Items related to uncertain tax positions during fiscal 2020 and 2019 included net tax impacts from the reversal of accruals for uncertain tax positions due to the expiration of statutes of limitations and the settlement of tax audits, the accrual of interest on uncertain tax positions, and the accrual of an uncertain tax position (fiscal 2020 only); and (iii) Other discrete tax items during fiscal 2020 and 2019 included net tax impacts as a result of changes in non-U.S. tax laws, return to provision adjustments related to tax return filings, and other items.

(F)

Includes tax impact of certain items and tax certain item for a valuation allowance charge recorded against U.S. deferred tax assets earned in fiscal 2020.

(G)

Per share amounts are calculated after tax and, where applicable, noncontrolling interest, net of tax.
Fourth Quarter Earnings Announcement, Fiscal 2020
 
 
CABOT CORPORATION RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
 
 
Fiscal 2020 (A)
Dec. Q Mar. Q June Q Sept. Q FY 2020
Reconciliation of Adjusted EPS to GAAP EPS
Net income (loss) per share attributable to Cabot Corporation

$

0.70

 

$

(0.01

)

$

(0.12

)

$

(4.81

)

$

(4.21

)

Less: Certain items after tax per share

 

0.01

 

 

(0.78

)

 

(0.05

)

 

(5.49

)

 

(6.29

)

Adjusted earnings (loss) per share

$

0.69

 

$

0.77

 

$

(0.07

)

$

0.68

 

$

2.08

 

 
Fiscal 2019 (A)
Dec. Q Mar. Q June Q Sept. Q FY 2019
Reconciliation of Adjusted EPS to GAAP EPS
Net income (loss) per share attributable to Cabot Corporation

$

1.14

 

$

0.39

 

$

0.55

 

$

0.55

 

$

2.63

 

Less: Certain items after tax per share

 

0.27

 

 

(0.60

)

 

(0.45

)

 

(0.50

)

 

(1.28

)

Adjusted earnings per share

$

0.87

 

$

0.99

 

$

1.00

 

$

1.05

 

$

3.91

 

Less: Specialty Fluids Adjusted earnings per share (B)

 

0.14

 

 

0.15

 

 

0.02

 

 

 

 

0.31

 

Adjusted earnings per share excluding Specialty Fluids

$

0.73

 

$

0.84

 

$

0.98

 

$

1.05

 

$

3.60

 

 
(A) Per share amounts are calculated after tax and, where applicable, noncontrolling interest, net of tax.
(B) Specialty Fluids Adjusted earnings per share is calculated as follows (in millions except for per share amounts):
Specialty Fluids EBIT

$

10

 

$

12

 

$

2

 

$

 

$

24

 

Less: Specialty Fluids taxes (C)

 

2

 

 

3

 

 

1

 

 

 

 

6

 

Specialty Fluids profit after tax

$

8

 

$

9

 

$

1

 

$

 

$

18

 

Divided by: Cabot Corporation diluted weighted average common shares outstanding

 

60.1

 

 

59.3

 

 

58.4

 

 

57.6

 

 

58.8

 

Specialty Fluids Adjusted EPS

$

0.14

 

$

0.15

 

$

0.02

 

$

 

$

0.31

 

(C) Specialty Fluids taxes calculated by applying Cabot’s Operating tax rate for each period to Specialty Fluids EBIT. Please refer to Cabot’s fiscal 2019 earnings releases for the reconciliations of the Company’s operating tax rate to its effective tax rate.
 
Dollars in millions Fiscal 2020
Dec. Q Mar. Q June Q Sept. Q FY 2020
Reconciliation of Segment EBIT to Net Income and Segment EBITDA Margin
Net income (loss) attributable to Cabot Corporation

$

41

 

$

(1

)

$

(6

)

$

(272

)

$

(238

)

Net income (loss) attributable to noncontrolling interests

 

5

 

 

4

 

 

1

 

 

7

 

 

17

 

Equity in earnings of affiliated companies, net of tax

 

 

 

(1

)

 

(1

)

 

(1

)

 

(3

)

Provision (benefit) for income taxes

 

4

 

 

10

 

 

(5

)

 

182

 

 

191

 

Income (loss) before income taxes and equity in earnings of affiliated companies

$

50

 

$

12

 

$

(11

)

$

(84

)

$

(33

)

Interest expense

 

14

 

 

14

 

 

13

 

 

12

 

 

53

 

Certain items

 

11

 

 

56

 

 

7

 

 

144

 

 

218

 

Unallocated corporate costs

 

10

 

 

12

 

 

10

 

 

9

 

 

41

 

General unallocated (income) expense

 

1

 

 

 

 

(2

)

 

2

 

 

1

 

Less: Equity in earnings of affiliated companies

 

 

 

(1

)

 

(1

)

 

(1

)

 

(3

)

Total Segment EBIT

$

86

 

$

95

 

$

18

 

$

84

 

$

283

 

Depreciation and amortization

 

39

 

 

39

 

 

39

 

 

41

 

 

158

 

Adjustments to depreciation (D)

 

(1

)

 

 

 

(1

)

 

 

 

(2

)

Total Segment EBITDA

$

124

 

$

134

 

$

56

 

$

125

 

$

439

 

Less: Unallocated corporate costs before corporate depreciation

 

10

 

 

12

 

 

10

 

 

8

 

 

40

 

Adjusted EBITDA

$

114

 

$

122

 

$

46

 

$

117

 

$

399

 

 
(D) Adjustments to depreciation includes the addition of the depreciation expense of a contractual joint venture in Purification Solutions less accelerated depreciation expense not allocated to a business.
 
Dollars in millions Dec. Q Mar. Q June Q Sept. Q FY 2020
Reinforcement Materials EBIT

$

47

 

$

61

 

$

(5

)

$

59

 

$

162

 

Reinforcement Materials Depreciation and amortization

 

17

 

 

17

 

 

17

 

 

17

 

 

68

 

Reinforcement Materials EBITDA

$

64

 

$

78

 

$

12

 

$

76

 

$

230

 

Reinforcement Materials Sales

$

379

 

$

355

 

$

197

 

$

325

 

$

1,256

 

Reinforcement Materials EBITDA Margin

 

17

%

 

22

%

 

6

%

 

23

%

 

18

%

 
Dollars in millions Dec. Q Mar. Q June Q Sept. Q FY 2020
Performance Chemicals EBIT

$

41

 

$

31

 

$

21

 

$

25

 

$

118

 

Performance Chemicals Depreciation and amortization

 

15

 

 

15

 

 

15

 

 

19

 

 

64

 

Performance Chemicals EBITDA

$

56

 

$

46

 

$

36

 

$

44

 

$

182

 

Performance Chemicals Sales

$

242

 

$

245

 

$

220

 

$

226

 

$

933

 

Performance Chemicals EBITDA Margin

 

23

%

 

19

%

 

16

%

 

19

%

 

20

%

 
Dollars in millions Dec. Q Mar. Q June Q Sept. Q FY 2020
Purification Solutions EBIT

$

(2

)

$

3

 

$

2

 

$ ―

$

3

 

Purification Solutions Depreciation and amortization

 

6

 

 

7

 

 

6

 

 

5

 

 

24

 

Purification Solutions EBITDA

$

4

 

$

10

 

$

8

 

$

5

 

$

27

 

Purification Solutions Sales

$

59

 

$

64

 

$

63

 

$

67

 

$

253

 

Purification Solutions EBITDA Margin

 

7

%

 

16

%

 

13

%

 

7

%

 

11

%

 
Dollars in millions Fiscal 2020
Reconciliation of Free Cash Flow and Discretionary Free Cash Flow to Cash Flow from Operating Activities Dec. Q Mar. Q June Q Sept. Q FY 2020
Cash flow from operating activities (E)

$

105

 

$

24

 

$

149

 

$

99

 

$

377

 

Less: Additions to property, plant and equipment

 

68

 

 

51

 

 

43

 

 

38

 

 

200

 

Free cash flow

$

37

 

$

(27

)

$

106

 

$

61

 

$

177

 

Plus: Additions to property, plant and equipment

 

68

 

 

51

 

 

43

 

 

38

 

 

200

 

Less: Changes in net working capital (F)

 

50

 

 

2

 

 

126

 

 

7

 

 

185

 

Less: Sustaining and compliance capital expenditures

 

30

 

 

27

 

 

24

 

 

21

 

 

102

 

Discretionary free cash flow

$

25

 

$

(5

)

$

(1

)

$

71

 

$

90

 

 
(E) As provided in the Condensed Consolidated Statements of Cash Flows.
(F) Defined as changes in accounts receivable, inventory and accounts payable and accrued liabilities as presented on the Condensed Consolidated Statements of Cash Flows.

 

Investor Contact: Steve Delahunt

(617) 342-6255

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Chemicals/Plastics Other Manufacturing Manufacturing

MEDIA:

Logo
Logo

Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or purchase warrants to purchase additional shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the size or terms of the proposed offering.

The Company plans to use the net proceeds from the offering to fund its continued research and development initiatives in connection with expanding its product pipeline including, but not limited to, investment in its ADXS-HOT program and for general corporate purposes. The Company may also use a portion of the net proceeds to acquire or invest in other businesses, products and technologies.

A.G.P./Alliance Global Partners is acting as sole book-running manager for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-226988) previously filed with the U.S. Securities and Exchange Commission (the “SEC”), and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) under the Securities Act, which became effective upon filing on August 30, 2018. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. Copies of the Supplement, the Base Shelf Prospectus and the Registration Statement may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected].

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Advaxis

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Such risks include, but are not limited to: the success and timing of the Company’s clinical trials, including patient accrual; the Company’s ability to develop and commercialize its products; the Company’s ability to identify license and collaboration partners and to maintain existing relationships; the Company’s available cash and its ability to obtain additional funding; and any outcomes from the Company’s review of strategic transactions. These and other risks are discussed in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on December 20, 2019, as amended, and its periodic reports on Form 10-Q and Form 8-K. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by law.

Investor Contact

Tim McCarthy
LifeSci Advisors, LLC
[email protected]
(212) 915-2564



Points Completes Amendment to its Credit Facility

TORONTO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Points International Ltd. (TSX: PTS) (Nasdaq: PCOM) (“Points” or the “Company”), the global leader in powering loyalty commerce, announced today that it has entered into an agreement to amend its existing senior secured credit facility (the “Amendment”) to provide covenant relief through June 30, 2021.

“With our operations now stabilized, we took a timely and proactive step to adapt our credit facility to the current environment,” said Rob MacLean, CEO of Points. “The amendment provides us with additional financial flexibility and ensures continued access to our facility during this unusual time, while strengthening an already solid balance sheet. I would like to thank our lending partners for their ongoing support and partnership.”

As a precautionary measure, Points drew down $40.0 million on its credit facility during the first quarter of 2020 in response to the early stages of the COVID-19 pandemic. Since that initial drawdown, Points elected to repay a total of $10.0 million over the course of the second and third quarter of 2020. At September 30, 2020, Points had over $64.0 million of cash and cash equivalents on its balance sheet, which included $30.0 million of borrowings on its facility. In the fourth quarter of 2020, Points and its lenders agreed to amend the credit facility to suspend the testing of its financial covenants for three quarters, beginning with the quarter ended December 31, 2020 through to the end of Q2 2021. These tests were calculated on a trailing twelve-month basis.

Under the terms of the amendment, the net senior leverage ratio, the interest coverage ratio, and the fixed charge coverage ratio, are replaced through to the end of Q2 2021 with a Minimum Adjusted EBITDA and a Minimum Liquidity test, with the company agreeing to extend the Minimum Adjusted EBITDA test two additional quarters. In addition, the Company agreed to reduce the facility size from $50.0 million to $40.0 million.

About Points International Ltd.

Points (TSX: PTS) (Nasdaq: PCOM) is a trusted partner to the world’s leading loyalty programs, using a unique Loyalty Commerce Platform to build, power, and grow new ways for members to get and use their favourite loyalty currency. Our platform combines insights, technology, and resources to make the movement of loyalty currency simpler and more intelligent for nearly 60 reward programs around the world. Founded in 2000, Points is headquartered in Toronto with teams operating around the globe.

For more information, please visit points.com.

Caution Regarding Forward-Looking Statements

This press release contains or incorporates forward-looking statements within the meaning of United States securities legislation, and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”). These forward-looking statements include or relate to but are not limited to, among other things, statements relating to plans the Company has implemented in response to the COVID-19 pandemic and its expected impact on the Company (including mitigation of the risk of a potential breach of its credit facility) and the Company’s ability to access the undrawn portion of its credit facility. These statements are not historical facts but instead represent only Points’ expectations, estimates and projections regarding future events.

Although Points believes the expectations reflected in such forward-looking statements are reasonable, such statements are not guarantees of future performance and are subject to important risks and uncertainties that are difficult to predict. Certain material assumptions or estimates are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Undue reliance should not be placed on such statements. In particular, uncertainty around the duration and scope of the COVID-19 pandemic and the impact of the pandemic and actions taken in response on global and regional economies, economic activity, and all elements of the travel and hospitality industry may have a significant and materially adverse impact on our business. In addition, the risks, uncertainties and other factors that may impact the results expressed or implied in such forward-looking statements include, but are not limited to: (i) airline or travel industry disruptions, such as an airline insolvency and continued airline consolidation; (ii) our dependence on a limited number of large clients for a significant portion of our consolidated revenue; (iii) our reliance on contractual relationships with loyalty program partners that are subject to termination and renegotiation; (iv) our exposure to significant liquidity risk if we fail to meet contractual performance commitments; (v) our ability to convert our pipeline of prospective partners or launch new products with new or existing partners as expected or planned; (vi) our dependence on various third-parties that provide certain solutions in our Platform Partners segment that we market to loyalty program partners; (vii) the fact that our operations are conducted in multiple jurisdictions and in multiple currencies and as such dramatic fluctuations in exchange rates of the foreign currencies can have a dramatic effect on our financial results and (viii) the risk of an event of default under our senior secured credit facility. These and other important risk factors that could cause actual results to differ materially are discussed in Points’ annual information form, Form 40-F, annual and interim management’s discussion and analysis (“MD&A”), and annual and interim financial statements and the notes thereto. These documents are available at www.sedar.com and www.sec.gov.

The forward-looking statements contained in this press release are made as at the date of this release and, accordingly, are subject to change after such date. Except as required by law, Points does not undertake any obligation to update or revise any forward-looking statements made or incorporated in this press release, whether as a result of new information, future events or otherwise.

Investor Relations Contact

Sean Mansouri, CFA or Cody Slach
Gateway Investor Relations
1-949-574-3860
[email protected]



Ambarella, Inc. Announces Third Quarter Fiscal Year 2021 Financial Results

SANTA CLARA, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — Ambarella, Inc. (Nasdaq: AMBA), an AI vision silicon company, today announced financial results for its third quarter of fiscal year 2021 ended October 31, 2020.

  • Revenue for the third quarter of fiscal 2021 was $56.1 million, down 17.4% from $67.9 million in the same period in fiscal 2020. For the nine months ended October 31, 2020, revenue was $160.8 million, down 6.2% from $171.5 million for the nine months ended October 31, 2019.
  • Gross margin under U.S. generally accepted accounting principles (GAAP) for the third quarter of fiscal 2021 was 62.0%, compared with 57.6% for the same period in fiscal 2020. For the nine months ended October 31, 2020, GAAP gross margin was 60.8%, compared with 57.9% for the nine months ended October 31, 2019.
  • GAAP net loss for the third quarter of fiscal 2021 was $17.1 million, or loss per diluted ordinary share of $0.49, compared with GAAP net loss of $4.3 million, or loss per diluted ordinary share of $0.13, for the same period in fiscal 2020. GAAP net loss for the nine months ended October 31, 2020 was $47.3 million, or loss per diluted ordinary share of $1.37. This compares with GAAP net loss of $31.8 million, or loss per diluted ordinary share of $0.97, for the nine months ended October 31, 2019.

Financial results on a non-GAAP basis for the third quarter of fiscal 2021 are as follows:

  • Gross margin on a non-GAAP basis for the third quarter of fiscal 2021 was 62.7%, compared with 58.1% for the same period in fiscal 2020. For the nine months ended October 31, 2020, non-GAAP gross margin was 61.4%, compared with 58.5% for the nine months ended October 31, 2019.
  • Non-GAAP net income for the third quarter of fiscal 2021 was $3.3 million, or earnings per diluted ordinary share of $0.09. This compares with adjusted non-GAAP net income of $11.3 million, or earnings per diluted ordinary share of $0.32, for the same period in fiscal 2020. Non-GAAP net income for the nine months ended October 31, 2020 was $6.7 million, or earnings per diluted ordinary share of $0.19. This compares with adjusted non-GAAP net income of $18.8 million, or earnings per diluted ordinary share of $0.55, for the nine months ended October 31, 2019.

Based on information available as of today, Ambarella is offering the following guidance for the fourth quarter of fiscal year 2021, ending January 31, 2021:

  • Revenue is expected to be between $56.0 million and $60.0 million.
  • Gross margin on a non-GAAP basis is expected to be between 59.0% and 61.0%.
  • Operating expenses on a non-GAAP basis are expected to be between $31.0 million and $33.0 million.

Ambarella reports gross margin, net income (loss) and earnings (losses) per share in accordance with GAAP and, additionally, on a non-GAAP basis. Non-GAAP financial information excludes the impact of stock-based compensation adjusted for the associated tax impact, which includes the effect of any benefits or shortfalls recognized. The non-GAAP net income for fiscal year 2021 includes a change in non-GAAP tax rate calculation to exclude losses from jurisdictions where there is no tax benefit associated to improve alignment of the non-GAAP income tax to the non-GAAP income (loss) before tax. Accordingly, non-GAAP net income and non-GAAP earnings per share for the third quarter and year-to-date of fiscal year 2020 ended October 31, 2019 have been adjusted for the change in non-GAAP income tax effect and presented consistent with fiscal year 2021 presentation. A reconciliation of the GAAP to non-GAAP gross margin, net income (loss) and earnings (losses) per share for the periods presented, as well as a description of the items excluded from the non-GAAP calculations, is included in the financial statements portion of this press release.

Total cash, cash equivalents and marketable debt securities on hand at the end of the third quarter of fiscal 2021 was $423.6 million, compared with $410.7 million in the prior quarter and $400.8 million at the end of the same quarter a year ago.

“Our AI vision portfolio is well positioned for the megatrends around security, safety and automation, and the pandemic appears to be accelerating the digital transformation,” said Fermi Wang, President and CEO. “We are announcing a significant automotive revenue funnel and providing a strong CV growth outlook. We have also recently added new CV customers in Asia, expanded our organization and strengthened our position in high volume markets with the introduction of CV28.”

Stock Repurchase

In the third quarter of fiscal year 2021, the company did not repurchase shares. During the second quarter of fiscal year 2021, Ambarella’s Board of Directors approved an extension of the prior $50.0 million repurchase program for an additional twelve months ending June 30, 2021. As of today, there are approximately $49.0 million available for repurchases under the program. The repurchase program does not obligate the company to acquire any particular amount of ordinary shares, and it may be suspended at any time at the company’s discretion.

Quarterly Conference Call

Ambarella plans to hold a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time today with Fermi Wang, President and Chief Executive Officer, and Casey Eichler, Chief Financial Officer, to discuss the third quarter of fiscal year 2021 results. The call can be accessed by dialing 877-304-8963 in the USA; international callers should dial 760-666-4834. Please dial in ten minutes prior to the scheduled conference call time. A live and archived webcast of the call will be available on Ambarella’s website at http://www.ambarella.com/ for up to 30 days after the call.

About Ambarella

Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power System-on-Chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements that are not historical facts and often can be identified by terms such as “outlook,” “projected,” “intends,” “will,” “estimates,” “anticipates,” “expects,” “believes,” “could,” or similar expressions, including the guidance for the fourth quarter of fiscal year 2021 ending January 31, 2021, and the comments of our CEO relating to our ability to take advantage of trends around security, safety and automation in the markets we address, the impact of the current health pandemic on the markets we address, our growth outlook, the company’s ability to generate design wins and potential revenue in the automotive market, our strategic position in the markets we address, and the competitive strength of our products, including new products such as the CV28 SoC. The achievement or success of the matters covered by such forward-looking statements involves risks, uncertainties and assumptions. Our actual results could differ materially from those predicted or implied and reported results should not be considered as an indication of our future performance.

The risks and uncertainties referred to above include, but are not limited to, risks associated with global health conditions and associated risk mitigation measures; global economic and political conditions, including possible trade tariffs and restrictions; revenue being generated from new customers or design wins, neither of which is assured; the commercial success of our customers’ products; our growth strategy; our ability to anticipate future market demands and future needs of our customers, including trends around security, safety and automation; our ability to introduce new and enhanced solutions; our ability to develop, and to generate revenue from, new advanced technologies, such as visual AI and computer vision functionality; our ability to develop, and to generate revenue from, new products; our ability to retain and expand customer relationships and to achieve design wins; the expansion of our current markets and our ability to successfully enter new markets, such as the OEM automotive and robotics markets; anticipated trends and challenges, including competition, in the markets in which we operate; our ability to effectively manage growth; our ability to retain key employees; and the potential for intellectual property disputes or other litigation.

Further information on these and other factors that could affect our financial results is included in the company’s Annual Report on Form 10-K for our 2020 fiscal year, which is on file with the Securities and Exchange Commission. Additional information will also be set forth in the company’s quarterly reports on Form 10-Q, annual reports on Form 10-K and other filings the company makes with the Securities and Exchange Commission from time to time, copies of which may be obtained by visiting the Investor Relations portion of our web site at www.ambarella.com or the SEC’s web site at www.sec.gov. Undue reliance should not be placed on the forward-looking statements in this release, which are based on information available to us on the date hereof. The results we report in our Quarterly Report on Form 10-Q for the third fiscal quarter ended October 31, 2020 could differ from the preliminary results announced in this press release.

Ambarella assumes no obligation and does not intend to update the forward-looking statements made in this press release, except as required by law.

Non-GAAP Financial Measures

The company has provided in this release non-GAAP financial information including non-GAAP gross margin, net income (loss), and earnings (losses) per share, as a supplement to the condensed consolidated financial statements, which are prepared in accordance with generally accepted accounting principles (“GAAP”). Management uses these non-GAAP financial measures internally in analyzing the company’s financial results to assess operational performance and liquidity. The company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting and analyzing future periods. Further, the company believes these non-GAAP financial measures are useful to investors because they allow for greater transparency with respect to key financial metrics that the company uses in making operating decisions and because the company believes that investors and analysts use them to help assess the health of its business and for comparison to other companies. Non-GAAP results are presented for supplemental informational purposes only for understanding the company’s operating results. The non-GAAP information should not be considered a substitute for financial information presented in accordance with GAAP, and may be different from non-GAAP measures used by other companies.

With respect to its financial results for the third quarter of fiscal year 2021, the company has provided below reconciliations of its non-GAAP financial measures to its most directly comparable GAAP financial measures. With respect to the company’s expectations for the fourth quarter of fiscal year 2021, a reconciliation of non-GAAP gross margin and non-GAAP operating expenses guidance to the closest corresponding GAAP measure is not available without unreasonable efforts on a forward-looking basis due to the high variability and low visibility with respect to the charges excluded from these non-GAAP measures. We expect the variability of the above charges to have a significant, and potentially unpredictable, impact on our future GAAP financial results.

AMBARELLA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
                 
    Three Months Ended October 31,   Nine Months Ended October 31,
      2020       2019       2020       2019  
                                 
Revenue   $ 56,090     $ 67,922     $ 160,848     $ 171,520  
                 
Cost of revenue     21,298       28,819       63,078       72,127  
Gross profit     34,792       39,103       97,770       99,393  
                 
Operating expenses:                
Research and development     36,573       32,480       103,575       95,917  
Selling, general and administrative     14,468       13,791       41,348       39,293  
                 
Total operating expenses     51,041       46,271       144,923       135,210  
                 
Loss from operations     (16,249 )     (7,168 )     (47,153 )     (35,817 )
                 
Other income, net     673       1,917       3,231       6,308  
                 
Loss before income taxes     (15,576 )     (5,251 )     (43,922 )     (29,509 )
                 
Provision (benefit) for income taxes     1,502       (942 )     3,375       2,302  
                 
Net loss   $ (17,078 )   $ (4,309 )   $ (47,297 )   $ (31,811 )
                 
Net loss per share attributable to ordinary shareholders:                
Basic   $ (0.49 )   $ (0.13 )   $ (1.37 )   $ (0.97 )
Diluted   $ (0.49 )   $ (0.13 )   $ (1.37 )   $ (0.97 )
Weighted-average shares used to compute net loss per share              
attributable to ordinary shareholders:                
Basic     34,819,880       33,304,171       34,460,172       32,885,729  
Diluted     34,819,880       33,304,171       34,460,172       32,885,729  
                 

The following table presents details of stock-based compensation expense included in each functional line item in the condensed consolidated statements of operations above:

  Three Months Ended October 31,   Nine Months Ended October 31,
    2020     2019     2020     2019
   
  (unaudited, in thousands)
Stock-based compensation:              
Cost of revenue $ 368   $ 335   $ 981   $ 922
Research and development   11,496     10,601     31,402     31,306
Selling, general and administrative   7,113     6,372     19,024     17,740
               
Total stock-based compensation $ 18,977   $ 17,308   $ 51,407   $ 49,968
               

The difference between GAAP and non-GAAP gross margin was 0.7% and 0.5%, or $368,000 and $335,000, for the three months ended October 31, 2020 and 2019, respectively. The difference between GAAP and non-GAAP gross margin was 0.6% and 0.6%, or $981,000 and $922,000, for the nine months ended October 31, 2020 and 2019, respectively. The differences were due to the effect of stock-based compensation.

AMBARELLA, INC.
RECONCILIATION OF GAAP TO NON-GAAP DILUTED EARNINGS (LOSSES) PER SHARE
(in thousands, except share and per share data)
               
  Three Months Ended October 31,   Nine Months Ended October 31,
    2020       2019       2020       2019  
   
  (unaudited)
GAAP net loss $ (17,078 )   $ (4,309 )   $ (47,297 )   $ (31,811 )
               
Non-GAAP adjustments:              
Stock-based compensation expense   18,977       17,308       51,407       49,968  
Income tax effect   1,407       (1,737 )     2,605       634  
Non-GAAP net income $ 3,306     $ 11,262     $ 6,715     $ 18,791  
               
GAAP – diluted weighted average shares   34,819,880       33,304,171       34,460,172       32,885,729  
Non-GAAP – diluted weighted average shares   35,801,017       34,789,673       35,469,263       34,052,772  
               
GAAP – diluted net loss per share $ (0.49 )   $ (0.13 )   $ (1.37 )   $ (0.97 )
Non-GAAP adjustments:              
Stock-based compensation expense   0.55       0.52       1.49       1.52  
Income tax effect   0.04       (0.05 )     0.08       0.02  
Effect of Non-GAAP – diluted weighted average shares   (0.01 )     (0.02 )     (0.01 )     (0.02 )
Non-GAAP – diluted net income per share $ 0.09     $ 0.32     $ 0.19     $ 0.55  
               

AMBARELLA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
         
  October 31,   January 31,  
    2020     2020  
         
ASSETS        
Current assets:        
Cash and cash equivalents $ 225,508   $ 231,403  
Marketable debt securities   198,129     173,345  
Accounts receivable, net   24,111     18,487  
Inventories   23,712     22,971  
Restricted cash   10     9  
Prepaid expenses and other current assets   4,777     4,975  
Total current assets   476,247     451,190  
         
Property and equipment, net   5,131     5,614  
Deferred tax assets, non-current   10,463     10,400  
Intangible assets, net   17,352     17,826  
Operating lease right-of-use assets, net   8,734     9,935  
Goodwill   26,601     26,601  
Other non-current assets   5,027     5,710  
         
Total assets $ 549,555   $ 527,276  
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
Current liabilities:        
Accounts payable   14,613     14,910  
Accrued and other current liabilities   41,922     34,970  
Operating lease liabilities, current   2,809     2,181  
Income taxes payable   1,711     691  
Deferred revenue, current   1,178     701  
Total current liabilities   62,233     53,453  
         
Operating lease liabilities, non-current   6,662     7,975  
Other long-term liabilities   18,007     17,776  
         
Total liabilities   86,902     79,204  
         
Shareholders’ equity:        
Preference shares        
Ordinary shares   16     15  
Additional paid-in capital   322,502     261,220  
Accumulated other comprehensive income   1,363     768  
Retained earnings   138,772     186,069  
Total shareholders’ equity   462,653     448,072  
         
Total liabilities and shareholders’ equity $ 549,555   $ 527,276  
         

Contact:

Louis Gerhardy
408.636.2310
[email protected]



Alico, Inc. to Participate at the Roth Virtual Deer Valley Consumer Event

FORT MYERS, Fla., Nov. 23, 2020 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that John Kiernan, the Company’s President and Chief Executive Officer, will participate at the Roth Virtual Deer Valley Consumer Event, to be held December 9-11, 2020.

The Company will be participating in virtual one-on-one and small group meetings on Friday, December 11, 2020. To schedule a meeting with Alico, please contact your Roth sales representative.

About
Alico

Alico, Inc. primarily operates two divisions: Alico Citrus, one of the nation’s largest citrus producers, and Alico Water Resources and Other Operations, a leading water storage and environmental services division. Learn more about Alico (Nasdaq: “ALCO”) at www.alicoinc.com.

Investor Contact:

Investor Relations
(646) 277-1254
[email protected]

Richard Rallo
Senior Vice President and Chief Financial Officer
(239) 226-2000
[email protected]



Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020.

The pre-recorded webcast of the fireside chat will be available under the “For Investors” section of the Antares Pharma website at www.antarespharma.com.

About Antares Pharma

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements within the meaning of the safe
harbor
provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the Company’s ability to achieve the 2020 full-year revenue guidance;
the uncertainty regarding the duration, scope and severity of the COVID-19 pandemic and the mitigation measures and other restrictions implemented in response to the same
and the impact on
demand for our products,
new patients and prescriptions, future revenue,
product supply, and our overall business, operating results and financial condition
; successful commercialization of NOCDURNA

®

in the United States and market acceptance and future revenue from the same
: commercial success of
XYOSTED

®

and future revenue from the same;
market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same;
whether the FDA will withdraw marketing approval for
Covis

Makena

®

subcutaneous auto injector following the recent FDA letter seeking withdrawal, whether
Covis
will be granted an appeal hearing and if granted, whether
Covis
will be successful and
future prescriptions, market acceptance and revenue from the same; Teva’s ability to successfully commercialize VIBEX

®

Sumatriptan Injection USP and the amount of revenue from the same; future prescriptions and sales of OTREXUP

®

; Teva’s ability to successfully commercialize generic teriparatide in 11 countries in Europe, Canada and Israel and future revenue from the same, successful development including the timing and results of the clinical bridging and Phase 3 clinical trial
of the drug device combination product for
Selatogrel
with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; FDA approval of Teva’s pending ANDA for generic
Forteo
and future revenue from the same; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development including Pfizer’s undisclosed development product; actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ”may”, ”will”, ”should”, ”would”, ”expect”, ”intend”, ”plan”, ”anticipate”, ”believe”, ”estimate”, ”predict”, ”potential”, ”seem”, ”seek”, ”future”, ”continue”, or ”appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, and in the Company’s other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contact:

Tram Bui
Vice President, Corporate Communications and Investor Relations
609-359-3016
[email protected] 



Dividend 15 Split Corp. Announces Preferred Share Offering

A high quality portfolio consisting of 15 dividend yielding Canadian Companies

TORONTO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Dividend 15 Split Corp. (the “Company”) is pleased to announce it will undertake an offering of Preferred Shares of the Company.

The offering will be led by National Bank Financial Inc.

The Preferred Shares will be offered at a price of $10.10 per Preferred Share to yield 5.45%.

The closing price on the TSX of the Preferred Shares on November 20, 2020 was $10.19.

Since inception of the Company, 200 consecutive dividends have been declared for the Preferred Shares. The aggregate dividends paid on the Preferred Shares have been $8.80 per share. All distributions to date have been made in tax advantage eligible Canadian dividends.

The net proceeds of the offering will be used by the Company to invest in an actively managed, high quality portfolio consisting of 15 dividend yielding Canadian companies as follows:

Bank of Montreal Enbridge Inc. TC Energy
The Bank of Nova Scotia Manulife Financial Corp. TELUS Corporation
BCE Inc. National Bank of Canada Thomson Reuters Corp.
Canadian Imperial Bank of Commerce Royal Bank of Canada The Toronto-Dominion Bank
CI Financial Corp. Sun Life Financial Inc. TransAlta Corporation

The Company’s investment objectives are:

Preferred Shares:

  1. to provide holders of the Preferred Shares with fixed, cumulative preferential monthly cash dividends in the amount of 5.50% annually; and
  2. on or about the termination date, currently December 1, 2024 (subject to further 5-year extensions thereafter and it has been extended in the past), to pay the holders of the Preferred Shares $10.00 per Preferred Share.

The sales period of this overnight offering will end at 9:00 a.m. EST on November 24, 2020. The offering is expected to close on or about November 30, 2020 and is subject to certain closing conditions including approval by the TSX.

A prospectus supplement to the Company’s short form base shelf prospectus dated June 18, 2020 containing important detailed information about the Preferred Shares and the Class A Shares being offered will be filed with securities commissions or similar authorities in all provinces of Canada. Copies of the prospectus supplement and the short form base shelf prospectus may be obtained from your registered financial advisor using the contact information for such advisor, or from representatives of the agents listed above. There will not be any sale or any acceptance of an offer to buy the securities being offered until the prospectus supplement has been filed with the Securities Commissions or similar authorities in each of the provinces of Canada.

For further information, please contact Dividend 15 Split Corp. Investor Relations at

416-304-4443 Toll free at 1-877-4-Quadra (1-877-478-2372) or visit www.dividend15.com



NuVasive to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

PR Newswire

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will participate in one-on-one investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2-3, 2020.

A pre-recorded fireside chat with management will be available to registered attendees of the conference during the week of November 23, 2020 and available online from the Investor Relations page of the Company’s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days.


About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company’s less invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company’s comprehensive procedural portfolio includes access, implants and fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in net sales, NuVasive has approximately 2,800 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com


Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasive-to-participate-in-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301178234.html

SOURCE NuVasive, Inc.

Nutanix Reports First Quarter Fiscal 2021 Financial Results

Nutanix Reports First Quarter Fiscal 2021 Financial Results

— Delivers Strong Start to the Fiscal Year with ACV Billings up 10% YoY

— Grows Run-rate ACV to $1.3 Billion, up 29% YoY

— Reaches Record-High New ACV from New Products, up 87% YoY

SAN JOSE, Calif.–(BUSINESS WIRE)–Nutanix, Inc. (NASDAQ: NTNX), a leader in private cloud, hybrid, and multicloud computing, today announced financial results for its first quarter ended October 31, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123006190/en/

Nutanix Q1FY21 Earnings Infographic (Graphic: Nutanix)

Nutanix Q1FY21 Earnings Infographic (Graphic: Nutanix)

“We are pleased with our financial performance in the first quarter, which marked a strong start to fiscal 2021 including increased adoption of new products as well as continued growth in our core hyperconverged infrastructure software,” said Dheeraj Pandey, Chairman, Co-Founder and CEO of Nutanix. “After launching our solutions on AWS in August, we announced a major partnership with Microsoft to develop our portfolio on Azure, placing the Nutanix HCI (Hybrid Cloud Infrastructure) at a significant competitive advantage to help our customers build out their hybrid and multicloud environments.”

“Our ACV-first strategy and solid go-to-market execution drove outperformance across all key financial metrics including ACV billings growth of 10 percent year-over-year and run-rate ACV growth of 29 percent year-over-year,” said Duston Williams, CFO of Nutanix. “Looking ahead, we remain focused on thoughtfully managing operating expenses as we continue to execute on our business model transformation and are confident in Nutanix’s ability to drive long-term growth for the benefit of all stakeholders.”

First Quarter Fiscal 2021 Financial Summary

 

Q1 FY’21

Q1 FY’20

Y/Y Change

Annual Contract Value (ACV)1 Billings

$137.8 million

 

$125.6 million

 

10%

Run-rate Annual Contract Value (ACV)2

$1.29 billion

 

$1.00 billion

 

29%

Total Average Contract Term3

3.5 years

 

3.9 years

 

(0.4) years

Total Revenue4

$312.8 million

 

$314.8 million

 

(0.6)%

GAAP Gross Margin

78.3%

 

77.1%

 

120 bps

Non-GAAP Gross Margin

81.9%

 

80.1%

 

180 bps

GAAP Operating Expenses

$426.9 million

 

$462.9 million

 

(8)%

Non-GAAP Operating Expenses

$341.2 million

 

$386.3 million

 

(12)%

Free Cash Flow

$(16.3) million

 

$(44.4) million

 

$28 million

Reconciliations between GAAP and non-GAAP financial measures and key performance measures are provided in the tables of this press release.

Recent Company Highlights

  • Entered into a Partnership with Microsoft Azure: Nutanix announced a new partnership with Microsoft that will enable both companies to deliver a hybrid cloud solution with seamless application, data, and license mobility as well as unified management across on-premises and Azure environments, using Nutanix HCI (Hybrid Cloud Infrastructure) on Azure.
  • Reset the Bar for Innovation in Hyperconverged Infrastructure Market: Nutanix introduced major new capabilities in its popular hyperconverged infrastructure software, delivering significant innovation to datacenter and cloud customers, which will result in up to 50% faster performance, easier cloud deployments with native virtual networking, simplified Zero-Trust security, and expanded automation and budgeting capabilities for cloud resources.
  • Expanded Innovation Including Launch of Karbon Container Technology: Additional innovation during the quarter continued in both the core platform and new products with announcements about new capabilities added to the hyperconverged infrastructure software platform, significant updates to the Database-as-a-Service solution (Era), as well as the launch of a new Kubernetes-based PaaS solution (Karbon Platform Services) to democratize containers beyond DevOps for IT operators, building on the AHV revolution to revolutionize hypervisors.
  • Introduced New Cloud Partner Program: Nutanix announced Elevate, a new global partner program, to simplify engagement for Nutanix’s entire partner ecosystem using a consistent set of tools, resources, and marketing platforms to take advantage of cloud business models. Under one integrated architecture, Elevate enables Value Added Resellers, Value Added Distributors, Service Providers and Telcos, Hyperscalers, Independent Software, Hardware, and Platform Vendors, Global System Integrators, and Services Delivery Partners to grow their business with hybrid and multicloud solutions.
  • Launched the Third Annual Enterprise Cloud Index, Showing Importance of Hybrid Cloud: For the third year, Nutanix partnered with a leading third-party research firm to analyze key trends and priorities in the industry. This year, the survey also provided a window into companies’ responses to COVID-19 and how it affected spending priorities. The research showed that IT leaders overwhelmingly (86%) continue to see hybrid cloud as the ideal deployment model, and that companies are taking important steps in their digital transformation journey including deploying hyperconverged infrastructure.
  • Expanded New Customer Base and New Business with Existing Customers: Despite the ongoing pandemic, Nutanix continued to add new customers, ending the first quarter of fiscal 2021 with a total of 18,040 end-customers. Further, Nutanix saw increased demand from new and existing customers for both new products and new workloads. First quarter customer wins included the following Global 2000 companies: Allianz (China) Insurance Holding Co., Ltd, CaixaBank, HCL Technologies Limited, Nomura Research Institute, Ltd., Royal Vopak, Teleperformance Colombia, and more.
  • Transformed .NEXT to Digital Experience: Nutanix held its largest ever .NEXT user conference this year, 100% virtually, with record attendance of over 40,000 prospects, customers and partners across multiple time zones and languages, resulting in a record weekly number of Test Drives and product trials. In addition, .NEXT is on track to deliver strong pipeline generation at a significantly lower cost than in-person events.

Second Quarter Fiscal 2021 Outlook

 

Q2 FY’21 Outlook

ACV Billings

$145-$148 million

Non-GAAP Gross Margin

Approximately 81.5%

Non-GAAP Operating Expenses

$360-$370 million

Weighted Shares Outstanding

Approximately 202 million

Supplementary materials to this press release, including our first quarter fiscal year 2021 earnings presentation, can be found at https://ir.nutanix.com/company/financial.

Webcast and Conference Call Information

Nutanix executives will discuss the company’s first quarter fiscal 2021 financial results on a conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time. To listen to the call via telephone, dial 1-833-227-5841 from within the United States or 1-647-689-4068 from outside the United States. The conference ID is 3994985. This call will be webcast live and available to all interested parties on our Investor Relations website at ir.nutanix.com. Shortly after the conclusion of the conference call, a replay of the audio webcast will be available on our Investor Relations website. A telephonic replay will be available for one week and can be accessed by calling 1-800-585-8367 or 1-416-621-4642, and entering the conference ID 3994985.

Definitions and Total Revenue Impact

1Annual Contract Value, or ACV, is defined as the total annualized value of a contract, excluding amounts related to professional services and hardware. The total annualized value for a contract is calculated by dividing the total value of the contract by the number of years in the term of such contract, using, where applicable, an assumed term of five years for contracts that do not have a specified term. ACV Billings for any given period is defined as the sum of the ACV for all contracts billed during the given period.

2Run-rate ACV at the end of any period, is the sum of ACV for all contracts that are in effect as of the end of that period. For the purposes of this calculation, the company assumes that the contract term begins on the date a contract is booked, irrespective of the periods in which we would recognize revenue for such contract.

3Total Average Contract Term represents the dollar-weighted term, calculated on a billings basis, across all subscription and life-of-device contracts, using an assumed term of five years for life-of-device licenses, executed in the quarter.

4Total Revenue was negatively impacted by year-over-year decline in average contract term associated with the ongoing transition to a subscription-based business model.

Non-GAAP Financial Measures and Other Key Performance Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial and other key performance measures: billings, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss, non-GAAP net loss per share, free cash flow, subscription revenue, subscription billings, Annual Contract Value billings (or ACV billings), Run-rate Annual Contract Value (or Run-rate ACV), and professional services billings. In computing these non-GAAP financial measures and key performance measures, we exclude certain items such as stock-based compensation and the related income tax impact, costs associated with our acquisitions (such as amortization of acquired intangible assets, income tax-related impact, and other acquisition-related costs), impairment of operating lease-related assets, change in fair value of derivative liability, amortization of debt discount and issuance costs, non-cash interest expense, other non-recurring transactions and the related tax impact, and the revenue and billings associated with pass-through hardware sales. Billings is a performance measure which we believe provides useful information to investors because it represents the amounts under binding purchase orders received by us during a given period that have been billed, and we calculate billings by adding the change in deferred revenue between the start and end of the period to total revenue recognized in the same period. Non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss, and non-GAAP net loss per share are financial measures which we believe provide useful information to investors because they provide meaningful supplemental information regarding our performance and liquidity by excluding certain expenses and expenditures such as stock-based compensation expense that may not be indicative of our ongoing core business operating results. Free cash flow is a performance measure that we believe provides useful information to our management and investors about the amount of cash generated by the business after necessary capital expenditures, and we define free cash flow as net cash used in operating activities less purchases of property and equipment. Subscription revenue, subscription billings, and professional services billings are performance measures that we believe provide useful information to our management and investors as they allow us to better track the growth of the subscription-based portion of our business, which is a critical part of our business plan. ACV billings and Run-rate ACV are performance measures that we believe provide useful information to our management and investors as they allow us to better track the topline growth of our business during our transition to a subscription-based business model because they take into account variability in term lengths. We use these non-GAAP financial and key performance measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. However, these non-GAAP financial and key performance measures have limitations as analytical tools and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Billings, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP net loss, non-GAAP net loss per share, and free cash flow are not substitutes for total revenue, gross margin, operating expenses, net loss, net loss per share, or net cash (used in) provided by operating activities, respectively; subscription revenue is not a substitute for total revenue; and subscription and professional services billings are not substitutes for subscription and professional services revenue, respectively. There is no GAAP measure that is comparable to either ACV billings or Run-rate ACV, so we have not reconciled either ACV billings or Run-rate ACV numbers included in this press release to any GAAP measure. In addition, other companies, including companies in our industry, may calculate non-GAAP financial measures and key performance measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures and key performance measures as tools for comparison. We urge you to review the reconciliation of our non-GAAP financial measures and key performance measures to the most directly comparable GAAP financial measures included below in the tables captioned “Reconciliation of Revenue to Billings,” “Disaggregation of Revenue and Billings,” “Reconciliation of Subscription and Professional Services Revenue to Subscription and Professional Services Billings,” “Reconciliation of GAAP to Non-GAAP Profit Measures,” and “Reconciliation of GAAP Net Cash Used In Operating Activities to Non-GAAP Free Cash Flow,” and not to rely on any single financial measure to evaluate our business.

Forward-Looking Statements

This press release contains express and implied forward-looking statements, including, but not limited to, statements regarding: our business plans, initiatives, objectives and outlook, including changes we have made or anticipate making in response to the COVID-19 pandemic and the launch of our new global partner program, our ability to manage our business during the pandemic, and the position we anticipate being in following the pandemic; our ability to execute such plans, initiatives and objectives successfully and in a timely manner, and the benefits and impact of such plans, initiatives and objectives, including our ability to manage our expenses and decrease our cash usage in future periods and drive long-term growth; the competitive market, including our competitive position, our projections about our market share and the size of our total addressable market; our customer needs and our response to those needs; the benefits and capabilities of our platform, solutions, products, services and technology, including the interoperability and availability of our solutions with and on third-party platforms; our plans and expectations regarding new products, services, product features and technology, including those that are still under development or in process; the success and impact of our customer, partner, industry, analyst, investor, and employee events on our business, including on future pipeline generation; our plans and timing for, and the success and impact of, our transition to a subscription-based business model and our changes in guidance metrics; the timing and potential impact of the COVID-19 pandemic on the global market environment and the IT industry, as well as on our business, operations and financial results, including the actions we have taken to manage operating expenses; and our guidance on estimated ACV Billings, non-GAAP gross margin, non-GAAP operating expenses and weighted shares outstanding for any future fiscal periods. These forward-looking statements are not historical facts and instead are based on our current expectations, estimates, opinions, and beliefs. Consequently, you should not rely on these forward-looking statements. The accuracy of these forward-looking statements depends upon future events and involves risks, uncertainties, and other factors, including factors that may be beyond our control, that may cause these statements to be inaccurate and cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by such statements, including, among others: failure to successfully implement or realize the full benefits of, or unexpected difficulties or delays in successfully implementing or realizing the full benefits of, our business plans, initiatives and objectives; the timing, breadth, and impact of the COVID-19 pandemic on our business, operations, and financial results, as well as the impact on our customers, partners, and end markets; failure to timely and successfully meet our customer needs; delays in or lack of customer or market acceptance of our new products, services, product features or technology; delays or unexpected accelerations in the transition to a subscription-based business model; the rapid evolution of the markets in which we compete; our ability to achieve, sustain and/or manage future growth effectively; factors that could result in the significant fluctuation of our future quarterly operating results, including, among other things, anticipated changes to our revenue and product mix, including changes as a result of our transition to a subscription-based business model, which will slow revenue growth during such transition and make forecasting future performance more difficult, the timing and magnitude of orders, shipments and acceptance of our solutions in any given quarter, our ability to attract new and retain existing end-customers, changes in the pricing of certain components of our solutions, and fluctuations in demand and competitive pricing pressures for our solutions; the introduction, or acceleration of adoption of, competing solutions, including public cloud infrastructure; and other risks detailed in our Annual Report on Form 10-K for the fiscal year ended July 31, 2020, filed with the U.S. Securities and Exchange Commission, or the SEC, on September 23, 2020. Additional information will also be set forth in our Quarterly Report on Form 10-Q that will be filed for the fiscal quarter ended October 31, 2020 which should be read in conjunction with this press release and the financial results included herein. Our SEC filings are available on the Investor Relations section of the company’s website at ir.nutanix.com and on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date of this press release and, except as required by law, we assume no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any of these forward-looking statements to reflect actual results or subsequent events or circumstances.

About Nutanix

Nutanix is a global leader in cloud software and a pioneer in hyperconverged infrastructure solutions, making computing invisible anywhere. Organizations around the world use Nutanix software to leverage a single platform to manage any app at any location for their private, hybrid and multicloud environments. Learn more at www.nutanix.com or follow us on Twitter @nutanix.

© 2020 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries. All other brand names mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). This press release contains links to external websites that are not part of Nutanix.com. Nutanix does not control these sites and disclaims all responsibility for the content or accuracy of any external site. Our decision to link to an external site should not be considered an endorsement of any content on such a site.

NUTANIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

 

 

As of

 

July 31,

2020

October 31,

2020

 

 

 

 

(in thousands)

Assets

 

 

Current assets:

 

 

Cash and cash equivalents

$

318,737

 

$

504,482

 

Short-term investments

 

401,041

 

 

813,603

 

Accounts receivable, net

 

242,516

 

 

183,270

 

Deferred commissions—current

 

68,694

 

 

76,047

 

Prepaid expenses and other current assets

 

63,032

 

 

56,719

 

Total current assets

 

1,094,020

 

 

1,634,121

 

Property and equipment, net

 

143,172

 

 

133,156

 

Operating lease right-of-use assets

 

127,326

 

 

126,542

 

Deferred commissions—non-current

 

146,834

 

 

167,711

 

Intangible assets, net

 

49,392

 

 

45,047

 

Goodwill

 

185,260

 

 

185,260

 

Other assets—non-current

 

22,543

 

 

24,035

 

Total assets

$

1,768,547

 

$

2,315,872

 

 

 

 

Liabilities and Stockholders’ Deficit

 

 

Current liabilities:

 

 

Accounts payable

$

54,029

 

$

48,272

 

Accrued compensation and benefits

 

109,109

 

 

115,725

 

Accrued expenses and other current liabilities

 

25,924

 

 

24,563

 

Deferred revenue—current

 

534,572

 

 

549,938

 

Operating lease liabilities—current

 

36,569

 

 

41,080

 

Total current liabilities

 

760,203

 

 

779,578

 

Deferred revenue—non-current

 

648,869

 

 

656,545

 

Operating lease liabilities—non-current

 

116,794

 

 

113,491

 

Convertible senior notes, net

 

490,222

 

 

994,637

 

Derivative liability

 

 

 

295,650

 

Other liabilities—non-current

 

27,436

 

 

33,326

 

Total liabilities

 

2,043,524

 

 

2,873,227

 

Stockholders’ deficit:

 

 

Common stock

 

5

 

 

5

 

Additional paid-in capital

 

2,245,180

 

 

2,299,903

 

Accumulated other comprehensive income

 

2,030

 

 

880

 

Accumulated deficit

 

(2,522,192

)

 

(2,858,143

)

Total stockholders’ deficit

 

(274,977

)

 

(557,355

)

Total liabilities and stockholders’ deficit

$

1,768,547

 

$

2,315,872

 

NUTANIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands, except per share data)

Revenue:

 

 

Product

$

192,444

 

$

155,752

 

Support, entitlements and other services

 

122,324

 

 

157,002

 

Total revenue

 

314,768

 

 

312,754

 

Cost of revenue:

 

 

Product (1)(2)

 

21,233

 

 

12,814

 

Support, entitlements and other services (1)

 

50,968

 

 

55,145

 

Total cost of revenue

 

72,201

 

 

67,959

 

Gross profit

 

242,567

 

 

244,795

 

Operating expenses:

 

 

Sales and marketing (1)(2)

 

291,838

 

 

257,290

 

Research and development (1)

 

138,206

 

 

135,804

 

General and administrative (1)

 

32,860

 

 

33,774

 

Total operating expenses

 

462,904

 

 

426,868

 

Loss from operations

 

(220,337

)

 

(182,073

)

Other expense, net

 

(5,040

)

 

(78,732

)

Loss before provision for income taxes

 

(225,377

)

 

(260,805

)

Provision for income taxes

 

3,923

 

 

4,243

 

Net loss

$

(229,300

)

$

(265,048

)

Net loss per share attributable to Class A and Class B common stockholders—basic and diluted

$

(1.21

)

$

(1.31

)

Weighted average shares used in computing net loss per share attributable to Class A and Class B common stockholders—basic and diluted

 

189,671

 

 

203,095

 

__________________________________________________

(1)

Includes the following stock-based compensation expense:

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Product cost of revenue

$

1,112

 

$

1,504

 

Support, entitlements and other services cost of revenue

 

4,751

 

5,761

Sales and marketing

 

27,775

 

 

32,227

 

Research and development

 

37,563

 

 

37,887

 

General and administrative

 

10,225

 

 

11,819

 

Total stock-based compensation expense

$

81,426

 

$

89,198

 

(2)

Includes the following amortization of intangible assets:

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Product cost of revenue

$

3,694

 

$

3,694

 

Sales and marketing

 

651

 

651

Total amortization of intangible assets

$

4,345

 

$

4,345

 

NUTANIX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Cash flows from operating activities:

 

 

Net loss

$

(229,300

)

$

(265,048

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Depreciation and amortization

 

22,462

 

 

23,499

 

Stock-based compensation

 

81,426

 

 

89,198

 

Change in fair value of derivative liability

 

 

 

64,740

 

Amortization of debt discount and debt issuance costs

 

7,635

 

 

11,708

 

Operating lease cost, net of accretion

 

6,671

 

 

8,347

 

Impairment of lease-related assets

 

 

 

2,822

 

Non-cash interest expense

 

 

 

1,952

 

Other

 

103

 

 

1,671

 

Changes in operating assets and liabilities:

 

 

Accounts receivable, net

 

30,592

 

 

60,094

 

Deferred commissions

 

(18,313

)

 

(28,230

)

Prepaid expenses and other assets

 

16,150

 

 

6,222

 

Accounts payable

 

5,208

 

 

(4,075

)

Accrued compensation and benefits

 

(4,786

)

 

10,041

 

Accrued expenses and other liabilities

 

(5,772

)

 

(1,238

)

Operating leases, net

 

(3,469

)

 

(7,970

)

Deferred revenue

 

65,230

 

 

22,194

 

Net cash used in operating activities

 

(26,163

)

 

(4,073

)

Cash flows from investing activities:

 

 

Maturities of investments

 

171,441

 

 

97,578

 

Purchases of investments

 

(321,474

)

 

(513,998

)

Sales of investments

 

7,870

 

 

 

Purchases of property and equipment

 

(18,203

)

 

(12,252

)

Net cash used in investing activities

 

(160,366

)

 

(428,672

)

Cash flows from financing activities:

 

 

Proceeds from sales of shares through employee equity incentive plans

 

23,973

 

 

19,600

 

Proceeds from the issuance of convertible notes, net of issuance costs

 

 

 

723,757

 

Repurchases of common stock

 

 

 

(125,079

)

Net cash provided by financing activities

 

23,973

 

 

618,278

 

Net (decrease) increase in cash, cash equivalents and restricted cash

$

(162,556

)

$

185,533

 

Cash, cash equivalents and restricted cash—beginning of period

 

399,520

 

 

321,991

 

Cash, cash equivalents and restricted cash—end of period

$

236,964

 

$

507,524

 

Restricted cash (1)

 

3,144

 

 

3,042

 

Cash and cash equivalents—end of period

$

233,820

 

$

504,482

 

Supplemental disclosures of cash flow information:

 

 

Cash paid for income taxes

$

7,779

 

$

5,050

 

Supplemental disclosures of non-cash investing and financing information:

 

 

Purchases of property and equipment included in accounts payable and accrued liabilities

$

12,200

 

$

2,948

 

__________________________________________________

(1)

Included within other assets—non-current in the condensed consolidated balance sheets.

Reconciliation of Revenue to Billings

(Unaudited)

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Total revenue

$

314,768

 

$

312,754

 

Change in deferred revenue

 

65,230

 

 

22,194

 

Total billings

$

379,998

 

$

334,948

 

Disaggregation of Revenue and Billings

(Unaudited)

 

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Disaggregation of Revenue:

 

 

Subscription

$

217,896

 

$

278,165

 

Non-portable software

 

77,571

 

 

20,043

 

Hardware

 

9,724

 

 

729

 

Professional services

 

9,577

 

 

13,817

 

Total revenue

$

314,768

 

$

312,754

 

 

 

 

Disaggregation of Billings:

 

 

Subscription

$

275,538

 

$

293,923

 

Non-portable software

 

77,571

 

 

20,043

 

Hardware

 

9,724

 

 

729

 

Professional services

 

17,165

 

 

20,253

 

Total billings

$

379,998

 

$

334,948

 

Subscription — Subscription revenue includes any performance obligation which has a defined term, and is generated from the sales of software entitlement and support subscriptions, subscription software licenses and cloud-based Software as a Service, or SaaS offerings.

  • Ratable We recognize revenue from software entitlement and support subscriptions and SaaS offerings ratably over the contractual service period, the substantial majority of which relate to software entitlement and support subscriptions.
  • Upfront Revenue from our subscription software licenses is generally recognized upfront upon transfer of control to the customer, which happens when we make the software available to the customer.

Non-portable software — Non-portable software revenue includes sales of our enterprise cloud platform when delivered on a configured-to-order appliance by us or one of our OEM partners. The software licenses associated with these sales are typically non-portable and have a term equal to the life of the appliance on which the software is delivered. Revenue from our non-portable software products is generally recognized upon transfer of control to the customer.

Hardware — In transactions where we deliver the hardware appliance, we consider ourselves to be the principal in the transaction and we record revenue and costs of goods sold on a gross basis. We consider the amount allocated to hardware revenue to be equivalent to the cost of the hardware procured. Hardware revenue is generally recognized upon transfer of control to the customer.

Professional services — We also sell professional services with our products. We recognize revenue related to professional services as they are performed.

Annual Contract Value Billings and Run-rate Annual Contract Value

(Unaudited)

 

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Annual Contract Value Billings (ACV Billings)

$

125,575

$

137,831

 

Run-rate Annual Contract Value (Run-rate ACV)

$

1,002,117

 

$

1,290,742

 

Reconciliation of Subscription and Professional Services Revenue to Subscription and Professional Services Billings

(Unaudited)

 

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Subscription revenue

$

217,896

 

 

$

278,165

 

Change in subscription deferred revenue

 

57,642

 

 

15,758

Subscription billings

$

275,538

 

 

$

293,923

 

 

 

 

 

Professional services revenue

$

9,577

 

 

$

13,817

 

Change in professional services deferred revenue

 

7,588

 

 

 

6,436

 

Professional services billings

$

17,165

 

 

$

20,253

 

Reconciliation of GAAP to Non-GAAP Profit Measures

(Unaudited)

 

 

GAAP

Non-GAAP Adjustments

Non-GAAP

 

Three Months Ended October 31, 2020

(1)

 

(2)

 

(3)

 

(4)

 

(5)

 

(6)

 

(7)

Three Months Ended October 31, 2020

 

 

 

 

 

 

 

 

 

 

 

(in thousands, except percentages and per share data)

Gross profit

$

244,795

 

$

7,265

 

$

3,694

 

$

287

 

$

 

$

$

$

$

256,041

 

Gross margin

 

78.3

%

 

2.3

%

 

1.2

%

 

0.1

%

 

 

 

 

 

 

 

 

 

81.9

%

Operating expenses:

 

 

 

 

 

 

 

 

 

Sales and marketing

 

257,290

 

 

(32,227

)

 

(651

)

 

 

 

 

 

 

 

 

 

 

 

224,412

 

Research and development

 

135,804

 

 

(37,887

)

 

 

 

(2,535

)

 

 

 

 

 

 

 

 

 

95,382

 

General and administrative

 

33,774

 

 

(11,819

)

 

 

 

 

 

(506

)

 

 

 

 

 

 

 

21,449

 

Total operating expenses

 

426,868

 

 

(81,933

)

 

(651

)

 

(2,535

)

 

(506

)

 

 

 

 

 

 

 

341,243

 

Loss from operations

 

(182,073

)

 

89,198

 

 

4,345

 

 

2,822

 

 

506

 

 

 

 

 

 

 

 

(85,202

)

Net loss

$

(265,048

)

$

89,198

 

$

4,345

 

$

2,822

 

$

506

 

$

64,740

 

$

13,660

 

$

393

 

$

(89,384

)

Weighted shares outstanding, basic and diluted

 

203,095

 

 

 

 

 

 

 

 

 

203,095

 

Net loss per share, basic and diluted

$

(1.31

)

$

0.44

 

$

0.02

 

$

0.02

 

$

 

$

0.32

 

$

0.07

 

$

 

$

(0.44

)

__________________________________________________

(1)

Stock-based compensation

(2)

Amortization of intangible assets

(3)

Impairment of lease-related assets

(4)

Other

(5)

Change in fair value of derivative liability

(6)

Amortization of debt discount and issuance costs and non-cash interest expense

(7)

Income tax effect primarily related to stock-based compensation expense

 

GAAP

Non-GAAP Adjustments

Non-GAAP

 

Three Months Ended October 31, 2019

(1)

 

(2)

 

(3)

 

(4)

 

(5)

Three Months Ended October 31, 2019

 

 

 

 

 

 

 

 

 

(in thousands, except percentages and per share data)

Gross profit

$

242,567

 

$

5,863

 

$

3,694

 

$

 

$

$

$

252,124

 

Gross margin

 

77.1

%

 

1.8

%

 

1.2

%

 

 

 

 

 

 

 

80.1

%

Operating expenses:

 

 

 

 

 

 

 

Sales and marketing

 

291,838

 

 

(27,775

)

 

(651

)

 

 

 

 

 

 

 

263,412

 

Research and development

 

138,206

 

 

(37,563

)

 

 

 

 

 

 

 

 

 

100,643

 

General and administrative

 

32,860

 

 

(10,225

)

 

 

 

(353

)

 

 

 

 

 

22,282

 

Total operating expenses

 

462,904

 

 

(75,563

)

 

(651

)

 

(353

)

 

 

 

 

 

386,337

 

Loss from operations

 

(220,337

)

 

81,426

 

 

4,345

 

 

353

 

 

 

 

 

 

(134,213

)

Net loss

$

(229,300

)

$

81,426

 

$

4,345

 

$

353

 

$

7,635

 

$

213

 

$

(135,328

)

Weighted shares outstanding, basic and diluted

 

189,671

 

 

 

 

 

 

 

189,671

 

Net loss per share, basic and diluted

$

(1.21

)

$

0.43

 

$

0.03

 

$

 

$

0.04

 

$

 

$

(0.71

)

__________________________________________________

(1)

Stock-based compensation

(2)

Amortization of intangible assets

(3)

Other

(4)

Amortization of debt discount and debt issuance costs

(5)

Income tax effect primarily related to stock-based compensation expense

Reconciliation of GAAP Net Cash Used In Operating Activities to Non-GAAP Free Cash Flow

(Unaudited)

 

Three Months Ended

October 31,

 

2019

2020

 

 

 

 

(in thousands)

Net cash used in operating activities

$

(26,163

)

$

(4,073

)

Purchases of property and equipment

 

(18,203

)

 

(12,252

)

Free cash flow

$

(44,366

)

$

(16,325

)

 

Investor Contact:

Shane Xie

[email protected]

Media Contact:

Jennifer Massaro

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Photo
Photo
Nutanix Q1FY21 Earnings Infographic (Graphic: Nutanix)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

Webcast and Conference Call Today at 4:30 p.m. ET

  • On track to initiate a Phase 2b study in adult transplant patients with respiratory syncytial virus by year-end and a Phase 2 study in pediatric patients with respiratory syncytial virus in early 2021
  • Readouts from two clinical trials in hepatitis B virus program expected in the second quarter of 2021
  • Initiated Phase 1 study of EDP-297, a highly potent and targeted follow-on farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis; initial clinical data expected in the second quarter of 2021
  • Royalty revenue for the quarter was $23.6 million
  • Cash and marketable securities totaled approximately $419 million at September 30, 2020

WATERTOWN, Mass.–(BUSINESS WIRE)–
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2020.

“2020 was marked by significant progress for Enanta. We initiated four clinical trials between our hepatitis B and non-alcoholic steatohepatitis programs, and we announced two new discovery programs for respiratory viruses – SARS-CoV-2 and human metapneumovirus. Additionally, we remain on schedule to initiate our adult transplant Phase 2b study in RSV by year-end 2020, which will be followed shortly thereafter with the initiation of our pediatric Phase 2 study in RSV in early 2021,” commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. “I am grateful to the entire Enanta team for rising to the challenges presented by the COVID-19 pandemic and advancing our existing pipeline. Our commitment has laid the groundwork for a strong 2021, with multiple catalysts anticipated next year, including clinical data in our lead disease areas. If positive, these data will strengthen Enanta as a leader in the discovery and development of small molecule drugs for viral infections and liver diseases, and position us well to progress further our wholly-owned pipeline of clinical and preclinical programs to bring meaningful new treatments to patients.”

FISCAL FOURTH QUARTER AND YEAR ENDED SEPTEMBER 30, 2020 FINANCIAL RESULTS

Total revenue of $23.6 million for the three months ended September 30, 2020 consisted of royalty revenue derived primarily from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir). Total revenue for the three months ended September 30, 2019, was $51.3 million. For the twelve months ended September 30, 2020, total revenue was $122.5 million compared to $205.2 million for the same period in 2019. The decrease in royalty revenue quarter over quarter was driven by lower HCV product sales as treated patient volumes have remained below pre-COVID levels, as reported by AbbVie.

Research and development expenses were $36.7 million for the three months ended September 30, 2020, compared to $38.7 million for the three months ended September 30, 2019. For the twelve months ended September 30, 2020, research and development costs were $136.8 million compared to $142.2 million in 2019. The decrease in research and development expenses was primarily due to the timing of the company’s clinical studies year over year and COVID-19-related delays in two clinical studies that are now ongoing.

General and administrative expenses totaled $6.7 million for the three months ended September 30, 2020, compared to $6.2 million for the three months ended September 30, 2019. For the twelve months ended September 30, 2020, general and administrative costs were $27.4 million compared to $26.2 million in 2019.

Enanta recorded income tax expense of $10.7 million for the three months ended September 30, 2020, despite a net operating loss, compared to an income tax benefit of $0.5 million for the same period in 2019. For the twelve months ended September 30, 2020, Enanta recorded income tax expense of $1.1 million, compared to an income tax benefit of $0.8 million for the twelve months ended September 30, 2019. The income tax expense in 2020 was due to a tax valuation allowance charge of $18.3 million recorded against the company’s deferred tax assets in the three months ended September 30, 2020. This is a non-cash charge based on an assessment that it is more likely than not that Enanta’s deferred tax assets will not be fully realized. The tax valuation allowance charge, which is recorded in income tax expense, was partially offset by a federal net operating loss carryback under the CARES Act, research and development credits generated during the year, and a release of an uncertain tax position reserve related to the close of a Massachusetts Department of Revenue Audit. In 2019, the company’s income tax benefit was the result of a federal tax benefit on foreign derived royalty income and tax deductions from employee stock-award-related activity during 2019.

Net loss for the three months ended September 30, 2020 was $29.3 million, or a loss of $1.46 per diluted common share, compared to net income of $9.2 million, or $0.44 per diluted common share, for the corresponding period in 2019. For the twelve months ended September 30, 2020, net loss was $36.2 million, or a loss of $1.81 per diluted common share, compared to net income of $46.4 million, or $2.21 per diluted common share for the twelve months ended September 30, 2019. The decrease in net income in both 2020 periods was due to a decrease in HCV royalties earned under the AbbVie agreement and a non-cash tax valuation allowance charge of $18.3 million recorded in the three months ended September 30, 2020.

Enanta’s cash, cash equivalents and marketable securities totaled approximately $419 million at September 30, 2020. This compares to a total of approximately $400 million at September 30, 2019. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for the foreseeable future.

FINANCIAL GUIDANCE FOR FISCAL YEAR 2021

  • Research and Development Expense: $145 million to $165 million
  • General and Administrative Expense: $27 million to $33 million

PIPELINE PROGRAMS AND BUSINESS REVIEW

Virology

Respiratory Syncytial Virus (RSV)

Enanta is evaluating EDP-938, its N-protein inhibitor, in a broad clinical development program, consisting of three planned or ongoing trials: RSVP, RSVTx and RSVPEDs. Together, these studies are designed to evaluate the effect of EDP-938 in a range of pediatric and adult patient populations:

  • RSVP, an ongoing Phase 2b study in adult outpatients with community-acquired RSV infection, is anticipated to readout data in 3Q 2021, subject to the impact of the ongoing COVID-19 pandemic on levels of community RSV infection and activities at trial sites.
  • RSVTx, a Phase 2b study in adult hematopoietic cell transplant recipients with acute RSV infection of the upper respiratory tract, is expected to initiate in 4Q 2020.
  • RSVPEDs, a Phase 2 study in hospitalized and non-hospitalized pediatric patients with RSV, is expected to initiate in early 2021.

Human Metapneumovirus (hMPV)

In January, Enanta announced a new program to develop nanomolar inhibitors of hMPV, a pathogen that causes upper and lower respiratory tract infections in young children and the elderly, as well as in immunocompromised patients or those with COPD or asthma. Enanta’s goal is to finalize a clinical candidate in 2021.

SARS-CoV-2 (COVID-19)

In March, Enanta initiated a program to discover direct-acting antiviral drug candidates, with a focus on polymerase and protease inhibitors, for the treatment of patients infected with the novel coronavirus COVID-19, also known as SARS-CoV-2. Enanta’s goal is to finalize a clinical candidate in 2021.

Hepatitis B Virus (HBV)

EDP-514, Enanta’s novel class II core inhibitor with Fast Track Designation from the FDA, is being developed in two Phase 1b studies for the treatment of HBV across different patient populations: subjects treated with a nucleos(t)ide reverse transcriptase inhibitor (NUC-suppressed patients), and chronic HBV subjects with high viral loads and not currently on therapy (viremic patients):

  • In February, Enanta announced positive results from Part 1 of a Phase 1a/1b clinical study, informing the company’s decision to initiate a Phase 1b study in NUC-suppressed patients in March. The Phase 1b study is currently ongoing with preliminary data expected in 2Q 2021.
  • Subsequently, in July, Enanta initiated a randomized, double-blind, placebo-controlled Phase 1b study in viremic chronic HBV subjects not currently on therapy, with preliminary data expected in 2Q 2021.

Non-Alcoholic Steatohepatitis (NASH)

EDP-305, Enanta’s lead farnesoid X receptor (FXR) agonist, is currently being evaluated for the treatment of NASH with fibrosis:

  • In May, Enanta announced that it was no longer pursuing an indication for EDP-305 in primary biliary cholangitis and would remain focused on NASH for this compound.
  • In August, Enanta began enrollment for ARGON-2, its Phase 2b randomized, double-blind, placebo-controlled 72-week study of EDP-305 in approximately 340 patients with biopsy-confirmed NASH with fibrosis, using doses of 1.5 mg and 2.0 mg.

EDP-297, Enanta’s highly potent and targeted follow-on FXR agonist is currently being developed for the treatment of NASH with fibrosis:

  • A Phase 1 randomized, double-blind, placebo-controlled, first-in-human clinical trial of EDP-297 is ongoing. Enanta expects to report safety, tolerability and pharmacokinetics data in 2Q 2021.

Around mid-year Enanta expects that the EDP-297 data, together with an interim analysis at 12 weeks of treatment on a subset of patients in ARGON-2, will enhance Enanta’s ability to prioritize its FXR agonist compounds and seek opportunities for development of one or both of them in combinations with other mechanisms for NASH with fibrosis.

UPCOMING EVENTS AND PRESENTATIONS

  • Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020
  • Evercore ISI 3rd Annual Virtual HealthCONx Conference, December 1 – 3, 2020
  • 39th Annual JP Morgan Virtual Healthcare Conference, January 11 – 14, 2021
  • Enanta plans to issue its fiscal first quarter 2021 financial results press release, and hold a conference call regarding those results, on February 8, 2021.

CONFERENCE CALL AND WEBCAST INFORMATION

Enanta will host a conference call and webcast today at 4:30 p.m. ET. To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on November 23, 2020, through 11:59 p.m. ET on November 25, 2020 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international callers. The passcode for both the live call and the replay is 5436807. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.

ABOUT ENANTA PHARMACEUTICALS, INC.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta’s clinical programs in RSV, NASH and HBV, as well as Enanta’s projections of its expenses in fiscal 2021, and its prospects for future royalty revenue from sales of AbbVie’s MAVYRET®/MAVIRET® regimen for HCV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the dependence of Enanta’s revenues in the short-term upon the continued success of AbbVie’s sales of its MAVYRET/MAVIRET HCV regimen; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV, NASH, HBV, hMPV and SARS-CoV-2; treatment rates, competitive pricing, and reimbursement rate actions affecting MAVYRET/MAVIRET compared to competitive HCV products on the market; the discovery and development risks of Enanta’s programs in RSV, NASH, HBV, hMPV and SARS-CoV-2; the competitive impact of development, regulatory and marketing efforts of others in those disease areas; any continuing impact of the COVID-19 pandemic on Enanta’s HCV royalties, business operations and clinical trials; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Form 10-Q for the quarter ended June 30, 2020, and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

Tables to Follow

 
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(in thousands, except per share amounts)
 
Three Months Ended Twelve Months Ended
September 30, September 30,

 

2020

 

2019

 

2020

 

2019

 
Revenue

$

23,631

 

$

51,313

$

122,473

 

$

205,197

Operating expenses
Research and development

 

36,686

 

 

38,719

 

136,756

 

 

142,213

General and administrative

 

6,728

 

 

6,163

 

27,356

 

 

26,246

Total operating expenses

 

43,414

 

 

44,882

 

164,112

 

 

168,459

Income (loss) from operations

 

(19,783

)

 

6,431

 

(41,639

)

 

36,738

Other income, net

 

1,149

 

 

2,274

 

6,620

 

 

8,819

Income (loss) before income taxes

 

(18,634

)

 

8,705

 

(35,019

)

 

45,557

Income tax (expense) benefit

 

(10,707

)

 

486

 

(1,149

)

 

826

Net income (loss)

$

(29,341

)

$

9,191

$

(36,168

)

$

46,383

Net income (loss) per share
Basic

$

(1.46

)

$

0.47

$

(1.81

)

$

2.37

Diluted

$

(1.46

)

$

0.44

$

(1.81

)

$

2.21

Weighted average common shares outstanding
Basic

 

20,074

 

 

19,686

 

19,940

 

 

19,584

Diluted

 

20,074

 

 

20,876

 

19,940

 

 

20,968

 
ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(in thousands)
 

September 30,

September 30,

2020

2019

Assets
Current assets
Cash and cash equivalents

$

87,131

$

51,230

Short-term marketable securities

 

299,518

 

284,006

Accounts receivable

 

23,492

 

51,313

Prepaid expenses and other current assets

 

26,696

 

15,299

Total current assets

 

436,837

 

401,848

Long-term marketable securities

 

32,634

 

65,013

Property and equipment, net

 

8,596

 

10,927

Deferred tax assets

 

345

 

11,341

Operating lease, right-of-use assets

 

7,020

 

Restricted cash

 

608

 

608

Other long-term assets

 

92

 

92

Total assets

$

486,132

$

489,829

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable

$

5,737

$

6,689

Accrued expenses and other current liabilities

 

14,159

 

15,920

Operating lease liabilities

 

4,261

 

Total current liabilities

 

24,157

 

22,609

Operating lease liabilities, net of current portion

 

3,838

 

Series 1 nonconvertible preferred stock

 

1,479

 

1,628

Other long-term liabilities

 

1,078

 

3,100

Total liabilities

 

30,552

 

27,337

Total stockholders’ equity

 

455,580

 

462,492

Total liabilities and stockholders’ equity

$

486,132

$

489,829

 

Investors and Media:

Jennifer Viera

617-744-3848

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo